PF-[ADDRESS_940917] OF A LOW- FAT 
AND HIGH -FAT MEAL ON THE RELATIVE BIOAVA ILABILITY OF PF-07284890
IN HEALTHY ADULT PAR TICIPANTS
Study Intervention Number : PF-
07284890
Study Intervention Name: N/A
USIND Number:
EudraCT Number: N/A
ClinicalTrials.gov ID: N/A
Pediatric Investigational Plan Number: N/A
Protocol Number: C4471002
Phase: 1
Brief Title: A Phase [ADDRESS_940918] of aLow-Fat and High- Fat Meal on 
the Relative Bioavailability  of PF-07284890 inHealthy  Adult Participants
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
PF-[ADDRESS_940919] OF FIGURES ...................................................................................................................8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................15
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................19
2.1. Study  Rationale .......................................................................................................19
2.2. Background .............................................................................................................19
2.2.1. Nonclinical Pharmacology ..........................................................................20
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................20
2.2.3. Nonclinical Safet y
......................................................................................20
2.2.4. Clinical Overview .......................................................................................22
[IP_ADDRESS]. First -in-Human Study  (C4471001) ................................ ........... 22
[IP_ADDRESS]. Summary  of PF -07284890 Pharmacokinetics in Human..........25
2.3. Benefit/Risk Assessment
.........................................................................................26
2.3.1. Risk Assessment .........................................................................................27
2.3.2. Benefit Assessment .....................................................................................28
2.3.3. Overall Benefit/Risk Conclusion ................................................................28
3. OBJECTI
VES AND EN DPOINTS .....................................................................................28
4. STUDY DESIGN .................................................................................................................28
4.1. Overall Design .........................................................................................................28
4.2. Scientific Rationale for Study  Design .....................................................................30
4.2.1. Assessment of Safety  Data Before Administration of the High
-fat 
Meal .................................................................................................................30
4.2.2. Choice of Contraception/Barri er Requirements ................................ ......... 31
4.2.3. Collection of Retained Research Samples ................................ .................. 31
4.3. Justification for Dose ..............................................................................................31
4.4. End of Study  Definition ..........................................................................................32
5. STUDY POPUL ATION
................................ ................................ ................................ ......32
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 45.1. I nclusion Criteria .....................................................................................................33
5.2.Exclusion Criteria ....................................................................................................33
5.3. L ifesty le Considerations ..........................................................................................36
5.3.1. Contraception ..............................................................................................36
5.3.2. Meals and Dietary  Restrictions ...................................................................36
5.3.3. Caffeine, Alcohol, and Tobacco .................................................................37
5.3.4. Activity .......................................................................................................38
5.3.5. Photosensitivity ...........................................................................................38
5.4. Screen Failures ........................................................................................................38
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................38
6.1. Study  Intervention(s) Administered ........................................................................38
6.1.1. Administration ............................................................................................39
6.2. Preparation, Handling, Storage, and Accountability ...............................................40
6.2.1. Preparation and Dispensing ........................................................................41
6.3. Assignment to Study I ntervention ...........................................................................41
6.4. Blinding
...................................................................................................................41
6.5. Study  Intervention Compliance ...............................................................................41
6.6. Dose Modification ...................................................................................................42
6.7. C ontinued Access to Study  Intervention After the End of the Study ......................42
6.8. Treatment of Overdose
............................................................................................42
6.9. Prior and Concomitant Therap y
..............................................................................42
6.9.1. Rescue Medicine .........................................................................................44
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................44
7.1. Discontinuation of Study  Intervention ....................................................................44
7.1.1. ECG Changes ..............................................................................................45
7.1.2. Potential Cases of Acute Kidney  Injury ................................ ..................... 45
7.1.3. COVID -19 ................................ ................................ ................................ ..45
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_940920] to Follow -up ....................................................................................................47
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 47

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 58.1. Administrative Procedures ......................................................................................47
8.2. Efficacy  Assessments ..............................................................................................48
8.3. Safet y Assessments .................................................................................................48
8.3.1. Phy sical Examinations ................................................................................49
8.3.2. Vital Signs ..................................................................................................49
[IP_ADDRESS]. Blood Pressure and Pulse Rate ..................................................49
[IP_ADDRESS]. Respi[INVESTIGATOR_82218] ........................................................................50
[IP_ADDRESS]. Temperature ..............................................................................50
8.3.3. E
lectrocardiograms.....................................................................................50
8.3.4. Ophthalmic Examinations
..........................................................................51
8.3.5. Clinical Safety  Laboratory  Assessments ....................................................51
8.3.6. COVID -19 Specific 
Assessments ...............................................................52
8.4. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................52
8.4.1. Time Period and Frequency  for Collecting AE and SAE Information .......52
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................53
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................53
8.4.2. Method of Detecting AEs and SAEs ..........................................................53
8.4.3. Follow -Up of AEs and SAEs ......................................................................54
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................54
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................54
[IP_ADDRESS]. Exposure During Pregnancy ......................................................55
[IP_ADDRESS]. Exposure During Breastfeeding ................................................56
[IP_ADDRESS]. Occupational Exposure .............................................................57
8.4.6. Cardiovascular and Death Events ...............................................................57
8.4.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_940921].............................................................57
[IP_ADDRESS]. Lack of Efficacy ........................................................................57
8.4.9. Medical Device Deficiencies ......................................................................57
8.4.10. Medication Errors .....................................................................................57
8.5. Pharmacokinetics ....................................................................................................58
8.5.1. Plasma for Anal ysis of PF -
07284890.........................................................58

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 68.6. Genetics ...................................................................................................................59
8.6.1. Specified Genetics ......................................................................................59
8.7. Biomarkers ..............................................................................................................60
8.7.1. Specified Gene Expression (RNA) Research .............................................60
8.7.2. Specified Protein Research .........................................................................60
8.7.3. Specified Metabolomic Research ...............................................................60
8.8. I mmunogenicit y Assessments .................................................................................60
8.9. Health Economics ...................................................................................................60
9. STATI STICAL CONSI DERATIONS
................................................................................60
9.1. Statistical Hy potheses .............................................................................................60
9.2. Analy sis Sets ...........................................................................................................61
9.3. Statistical Analy ses.................................................................................................61
9.3.1. Primary  Endpoint(s) Anal ysis.....................................................................61
[IP_ADDRESS]. Definition of Endpoint(s)
..........................................................61
[IP_ADDRESS]. Statistical Methods for Pharmacokinetic Data ..........................62
9.3.2. Other Safet y Analyses ................................................................................63
[IP_ADDRESS]. Electrocardiogram Analy ses......................................................63
9.4. I nterim Anal yses.....................................................................................................64
9.5. Sample Size Determination .....................................................................................64
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................66
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............66
10.1.1. Regulatory and Ethical Considerations ....................................................66
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................66
10.1.2. I nformed Consent Process ................................ ................................ ........ 67
10.1.3. Data Protection .........................................................................................68
10.1.4. Committees Structure ...............................................................................68
10.1.5. Dissemination of Clinical Study  Data ......................................................68
10.1.6. Data Qualit y Assurance ............................................................................69
CCI
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 710.1.7. Source Documents ....................................................................................71
10.1.8. Study  and Site Start and Closure ................................ .............................. 71
10.1.9. Publication Policy.....................................................................................72
10.1.10. Sponsor’s Medically  Qualified Individual ..............................................73
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................74
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................76
10.3.1. Definition of AE .......................................................................................76
10.3.2. Definition of an SAE ................................................................................77
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................78
10.3.4. Reporting of SAEs
....................................................................................82
10.4. Appendix 4: Contraceptive 
and Barrier Guidance ................................................83
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................83
10.4.2. Female Participant Reproductive Inclusion Criteria .................................83
10.4.3. Woman of Childbearing Potential ............................................................83
10.4.4. Contraception Methods .............................................................................84
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......87
10.7. Appendix 7: Kidney  Safety : Monitoring Guidelines ............................................89
10.7.1. Laboratory  Asses sment of Change in Kidney
 Function and 
Detection of Kidney  Injury ..............................................................................89
10.7.2. Age -Specific Kidney  Function Calculation Recommendat
ions...............89
[IP_ADDRESS]. Adults (18 Years and Above) —2021 CKD - EPI 
[INVESTIGATOR_185560] ...........................................................................................89
10.7.3. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities ...................................................................................................89
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ................................ ...90
10.9. Appendix 9: Prohibited Concomitant Medications That May Result in DDI .......92
10.10. Appendix 10: Abbreviations ...............................................................................[ADDRESS_940922] OF TABLES
Table 1. MOEs for Nonclinical Species Compared to Humans at Dose 
Levels of Interesta.....................................................................................21
Table 2. PF-07284890 Monotherapy  Dose Level Review and Status ....................24
Table 3. PF-
07284890 Combination with Binimetinib (45 mg BID) Dose 
Level Review and Status ..........................................................................25
Table 4. PF-07284890 Plasma PK Parameters Observed During 
Monotherap y Dose Escalation in C4471001a...........................................25
Table 5. PF-07284890 Plasma PK Parameters Observed During 
Combination Dose Escalation in C4471001a............................................26
Table 6. Plasma PF -
07284890 PK Parameters Definitions ....................................62
Table 7. Confidence Interval Estimation of PK Endpoints ....................................64
Table 8. Protocol -Required Safet y Laboratory  Assessments .................................74
Table 9. Protocol -Required Follow -Up Safet y Laboratory  Assessments (In 
Case of Abnormalit y)...............................................................................[ADDRESS_940923] OF FIGURES
Figure 1. C4471001 Study  Schema ..........................................................................15

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Protocol Title: A Phase 1, Open-L abel, Randomized, Single Dose, [ADDRESS_940924] of a Low- fat and High- fat Meal on the Relative 
Bioavailability  of PF-07284890 in Healthy  Adult Participants 
Brief Title: A Phase [ADDRESS_940925] of a Low- Fat and High -Fat Meal on the 
Relative Bioavailability  of PF-07284890 in Healthy  Adult Participants
Regulatory Agency Identification Number(s):
US IND Number:
EudraCT Number: N/A
ClinicalTrials.gov ID: N/A
Pediatric Investigational Plan Number: N/A
Protocol Number: C4471002
Phase: 1
Rationale :
The purpose of the study  is to evaluate the effect of a low-fat and high -fat meal on the 
relative bioavailabilit y of PF-[ADDRESS_940926] -in-patient 
study  C4471001 (200 mg per single dose) .
Objectives and E ndpoints :
Objectives Endpoints
Primary: Primary: 
To evaluate the effect of a low- fat meal on the 
exposures of PF -07284890 following a single oral 
200-mg dose
To evaluate the effect of a high -fat meal on the 
exposures of PF -07284890 following a single oral 
200-mg doseComparison of low -fat meal with fasted PK: The ratio of 
AUC last, AUC inf(if data permit) and C maxof 
PF-07284890
Comparison of high -fat meal with fasted PK: The ratio 
of AUC last, AUC inf(if data permit) and C maxof 
PF-07284890
Secondary: Secondary: 
To characterize the pharmacokinetic parameters of 
PF-07284890 following a single oral 200 -mg doseTmax, t½, CL/F and V z/F (if data permit).
To evaluate the safety and tolerability of PF-07284890 
in healthy participantsAssessment of TEAEs, clinical laboratory abnormalities, 
vital signs, and 12 -lead ECGs.
Overall Design :
This is a Phase 1, open- label, randomized , single dose, 3-treatment, 2-sequence, 3- period 
crossover study to evaluate the effect of a low-fat and high -fat meal on the relative 
CCI
PF-[ADDRESS_940927] of 3 treatments: a single oral dose of 
200mg PF- 07284890 (2 × 1 00 mg tablets) under fasted conditions (Treatment A , Reference ), 
a single oral dose of 200mg PF- 07284890 (2 × 1 00mg tablets) under low-fat meal fed 
conditions (Treatment B, Test 1 ), and a single oral dose of 200 mg PF-07284890 (2 × 1 00mg 
tablets) under high-fat meal fed conditions 
(Treatment C, Test 2). 
Approximately  12 healthy  participants will be randomly  assigned to study  intervention such 
that approximately  6 participants will be enrolled to each sequence . Participants who 
discontinue from the study for non -
safet y reasons may be replaced at the sponsor’s discretion 
in collaboration with the investigator.
Health y participants will be screened to determine eligibility  within [ADDRESS_940928] 12 hours prior to the dosing of 
PF-
07284890 on Day  1of Period 1. O n the morning of Day  1 of each period, participants 
will receive a single dose of PF-07284890 200 mgas per randomization schedule . Study  
intervention will be administered with approximately  240 mL of ambient temperature water. 
In fed periods ( Sequence 2
Period 1 and Sequence 1 Period 2 for the low -fat meal and 
Period 3for the high-fat meal as shown in Section 1.2), following an overnight fast of at least 
10hours, participants should begin breakfast approximately  30 minutes prior to 
PF-
07284890 administration. For Sequence 2 Period 1 and Sequence 1 Per iod 2, alow-fat 
(approximately  25% of total caloric content of the meal), low-calorie (approximately  400to 
500 calories) breakfast will be consumed over approximately  a 20 - minute interval with 
PF-07284890 administered within approximately 10 minutes of c ompletion of the meal. For 
Period 3, a high-fat (approximately  50% of total caloric content of the meal), high- calorie 
(approximately  800 to 1000 calories) breakfast will be consumed over approximately  a 
20-minute interval with PF- [ADDRESS_940929] dose. 
Period 2 will begin on Period 1 Study  Day  5(referred to as Period 2, Day  -1). Period 3 will 
begin on Period 2 Study  Day  5 (referred to as Period 3, Day  -1). Participants will be 
discharged from the CRU at the end of Period [ADDRESS_940930] 8 participants administered a low -fat meal 
in Period 1 or 2 , will be reviewed b y the stud y team and the investigator and assessed based 
on safet y and tolerability . Period 
3 will initiate as planned if the d osesadministered in 
Period s 1 and 2 werewell- tolerated.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 11If a participant has an y clinically  significant, study related abnormalities at the conclusion of 
a scheduled inpatient portion of the study , the [COMPANY_007] medical monitor (or designated 
representative ) should be notified and the participant may  be asked to remain in the CRU 
until such abnormalities are deemed not clinicall y significant, or it is safe for outpatient 
follow -up.
A safet y follow- up call will be made to participants 28 to 35 day s from administration of the 
final dose of stud y intervention.
Number of Participants:
Approximately  12participants will be randomly  assigned to study  intervention .
Note: "Enrolled" means a participant ’
sagreement to participate in a clinical study  following 
completion of the informed consent process andassignment to study  intervention . A 
participant will be considered enrolled if the informed consent is not withdrawn prior to 
participating in an y study activity . Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in the study , are not considered 
enrolled, unless otherwise specified b y the protocol.
Study Population: 
Inclusion and exclusion criteria are listed below:
Inclusion Criteria 
Participants must meet the following inclusion criteria to be eligible for enrollment into the 
study :
1.Participants ≥18 and 65years of age, inclusive, at the time of signing the ICD . 
2.Male participants 
and female participants of non -childbearing potential who are 
overtly  healthy  as determined by  [CONTACT_336261] , 
physical examination, laboratory  tests, vital signs and 12
-lead ECGs .
3.BMI of 17.5 to 30 .5kg/m2; and a total body  weight >50 kg (110 lb).
4.Participants who are willing a nd able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
5.Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 12Exclusion Criteria 
Participants with any  of the following characteristics/conditions will be excluded:
1.Evidence or history  of clinically  significant uveitis, hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
Any condition possibly  affecting drug absorption (eg, gastrectomy , 
cholecy stectom y). 
History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, 
HBsAg, HBcAb or HCVAb. Hepatitis B vaccination is allowed.
Use of PPI s is not allowed within 7 day s ofstudy  start (C1D1) and during study  
treatment.
2.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg , contact [CONTACT_216478], residence, 
or travel to an area with high incidence) that may  increase the risk of study 
participation or, in the investigator’s judgment, make the participant inappropriate for 
the study .
3.Use of prescription or nonprescriptio n drugs and dietary  and herbal supplements 
within 7 day s or 5 half -lives (whichever is longer) prior to the first dose of study  
intervention.
4.Current use or anticipated need for drugs that are known strong UGT2B7 inhibitors,
including the administration wi thin [ADDRESS_940931] (drug or vaccine) within 
30days (or as determined by  [CONTACT_19970]) or [ADDRESS_940932] 
dose of study  intervention used in this study  (whichever is longer).
7.Positive test result (RT -PCR) for SARS -CoV -[ADDRESS_940933] at screening or admission.
10.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_940934], if deemed necessary : 
AST or ALT level ≥1.25 × ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history  of Gilbert’s 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ULN.
eGFR < 75mL/min/1.73 m2with 10% variation based on the CKD -EPI [INVESTIGATOR_10908].
Hemoglobin < 11 g/dL
ANC < 1.5 10e9/L
Platelets < 100,000/mm3
13.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
depende nce within 6 months of Screening.
14.Current smokers or history  of the use of tobacco
- or nicotine- containing products 
within 6 months of screening.
15.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL)or 
more within 60days prior to dosing .
16.History  of sensitivity  to heparin or heparin -induced thrombocy topenia . 
17.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol.
18.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 14Study Arms and Duration:
Each participant will be screened to determine eligibility  within 28 days prior to study  
treatment. Eligible participants will report to the CRU on Day  -1, Period 1 and will be 
required to stay  in the CRU for 15days and 14 nights. A safet y follow-up call will be made 
to participants 28 to 35 day s from administration of the final dose of study  intervention. 
Each enrolled participant will participate in 3study  periods to receive 3 different treatments
according to the sequ ence determined b y randomization with 5-daywashouts between
PF-07284890 administration : 
Treatment A: Single oral dose of 200 mg PF-07284890 (2 × 100 mg tablets) under fasted 
conditions (Reference) .
Treatment B: Single oral dose of 200 mg PF-07284890 (2 × 1 00 mg tablets) under fed 
conditions, low -fat meal (Test 1).
Treatment 
C: Single oral dose of 200 mg PF-07284890 (2 × 1 00 mg tablets) under fed 
conditions
, high -fat meal (Test 2).
Participants will be randomly  assigned to 1 of 2 sequences as shown in Section 1.2.
Statistical Methods :
Pharmacokinetics Analy sis
The PK concentration population is defined as all participants randoml y assigned to stud y 
intervention and who take at least [ADDRESS_940935] noncompartmental method 
of anal ysis. Actual PK sampling times will be used in the derivation of PF-07284890 PK 
parameters when available, otherwise nominal times will be used. The PF-07284890 plasma 
PK parameters will be summarized descriptively  by [CONTACT_3148]. Plasma concentrations will be 
listed and summarized descriptively  by [CONTACT_3148], and nominal PK sampling time. Individual 
participant and summary  profiles (mean and median plots) of the plasma concentration- time 
data will be plotted by  [CONTACT_486832], respectively . 
Natural log transformed AUC inf(if data permit), AUC lastand C maxwill be anal yzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect. Estimates of the adjusted mean differences (Test -
Reference) and corresponding 90% CIs will be obtained fro m the model. The adjusted mean 
differences and 90% CIs for the differences will be exponentiated to provide estimates of the 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 15ratio of adjusted geometric means (Test/Reference) and 90% CI for the ratios. Treatment A 
(PF-07284890 administered under fasted condition) is the Reference treatment ,Treatment B 
(PF-07284890 administered under fed condition , low -fat meal) is the first Test treatment , 
Test 1, and Treatment C ( PF-
07284890 administered under fed condition, high -fat meal) is 
the second Test treatment, T est 2. 
Safety  Anal ysis
All safet y anal yses will be performed on the safet y anal ysis set, which is defined as all 
participants randoml y assigned to stud y intervention and who take at least 1 dose of study 
intervention. Safet y data will be presented in tabu lar and/or graphical format and summarized 
descriptivel y, where appropriate.
Ethical Considerations:
PF-07284890 is not expected to provide an y clinical benefit to health y participants. This 
study  is designed primarily  to generate PK, safet y and tolerabili tydata for PF-07284890 
administered in the fasted and fed state for further clinical development.
Participants will be expected to commit time and may experience some discomfort 
while undergoing study  assessments. 
Male participants must agree to use appr opriate contraception methods.
1.2.Schema
A diagram of the stud y design is display ed in Figure 1.
Figure 1.C4471002 Study Schema

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 161.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in additi on to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 10ScreeningaPeriods 1 -3b
Follow -UpEarly 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_940936]
Hours After Dose 00.5 11.5 22.5 3 4 6 812 16 24364872
Informed consent X
CRU confinementcX                X
Inclusion/exclusion criteria X X
Medical/medication history 
(update)dX X
DemographyeX
Physical exami nationfX Xf
Safety laboratory (including 
aPTT, PT -INR and eGFR)gX XvX X
FSHhX
Urine drug and cotinine 
testingiX X
HIV, HBsAg, HBcAb,
HCVAbX
Contraception checkjX X X X
Single supi[INVESTIGATOR_050] 12 -lead ECGkX X X X X X
Triplicate 12-lead ECGkXs
Vital signs 
(BP/PR/temperature)lX XsX X
Full ophthalmic exammIf clinically indicated 
COVID -19 questionnairenX X

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 17Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 10ScreeningaPeriods 1 -3b
Follow -UpEarly 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_940937]
Hours After Dose 00.5 11.5 22.5 3 4 6 812 16 24364872
COVID -19 testingnX X  
PF-07284890oX
PK blood sampling for 
PF-07284890pXsX X X X X X X X X X X X X X X X
Retained Research Sample 
for Genetics (Prep D1)qX
Serious and nonserious AE 
monitoringX                  X X
Concomitant treatments  X              X X
CRU dischargerX
a. Screening will be performed within [ADDRESS_940938] dose of PF -07284890 . 
b. Period 2 will begin on Study Period 1, Day 5(referred to as Period 2, Day -1).Period 3will begin on Study Period 2, Day 5(referred to as Period 3, Day -1).Day -[ADDRESS_940939] 12 hours prior to PF-07284890 dose on Day 1 of Period 1 .Participants will be discharged on Day 4 of Study Period 3
following completion of all assessments.
d. Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as well as blood donation within prio r 60days. Medical history will be recorded at 
screening and updated on Day -1 of Period 1. 
e. Demographics will include participant race, ethnicity, age, and gender during the screening visit. 
f. Physical exami nation will be performed by [CONTACT_487227] -1 of Period 1 only (height and weight must be obtained at 
screening to obtain BMI for eligibility criteria). A brief PE will be performed on Day -[ADDRESS_940940]. Additional safety laboratory assessments may be 
performed at any time at the discretion of the investigator. 
h. For postmenopausal (amenorrheic for at least 12 consecutive months) female participants only.
i. Urine drug and cotinine (mandatory) and alcohol breath test (at discretion of the investigator) will be performed at screening from Days -28 to -2 and again on Day -1of 
Period 1. These tests may be performed at any other time at the discretion of the investigator.
j. The investigator or his/her designee will discuss with the participant the need to use highly effective contraception consisten tly and correctly according to contraception 
guidelines.
k. All ECG assessments will be made after at least a 5-minute rest in a supin e position and prior to any blood draws or vital sign measurements. Day 4ECGs are for Period 3 
only. Single ECGs are needed for screening, times after the study intervention has been administered ,Day 4of Period 3 , and upon early termination/discontinuat ion, while 
triplicate ECGs are needed for baselin e.
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 18Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 10ScreeningaPeriods 1 -3b
Follow -UpEarly 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_940941] practice. RR will be 
collected if the PR is outside of normal range.
m. Full ophthalmic exam will be conducted if treatment emergent ocul ar AEs are observed.
n. See Section 8.3.6 for details .
o. PF-07284890 will be administered orally on Day 1 after overnight fasting until the start of study procedures for each treatment period. PF-07284890 will be administered orally 
and in fasted or fed state according to the conditions described in Protocol Section 5.3.2 Meals and Dietary Restrictions .
p. One (approximately 3mL) blood sample for PK analysis of PF-[ADDRESS_940942] dose in each treatment period .
q. Retained Research Samples Prep D1 for Genetics: If not collected on the designated collection day, collect at the next available time point when biospecimens a re being 
collected in conjunction with a participant visit. These samples will be collected during Period [ADDRESS_940943] at pre -dose for all 3 periods. For fed periods (Sequence 2 Period 1 and Sequence 1 Period 2 for the low-fat meal and Period 3 for the high -fat meal ), the ECG sshould 
be don e before the pre -dose PK sample , and both should be done before the meals .
t. Contact [CONTACT_693754] 28 to 35 days from administration of the final dose of study intervention.
v. Safety laboratories w ill be done on Day -1 of all 3 periods.
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 192.INTRODUCTION
PF-07284890 (also known as ARRY -461) is a potent, selective, highl y brain -penetrant 
small -molecule inhibitor of BRAF V600 mutations that is currentl y being developed for the 
treatment of BRAF V600 -
mutant solid tumors with or without brain involvement.
2.1.Study Rationale 
The purpose of the study  is to evaluate the effect of a low- fat and high-fat meal on the 
relative bioavailabilit y of PF-[ADDRESS_940944] -in-patient 
study  C4471001 (200 mg per single dose) . Results from the study  will be used to inform food 
instructions for patients in PF -[ADDRESS_940945] -in-patient study  C4471001, Phase 1b.
2.2.Background 
BRAF V600 mutations occur in approximately  50% of melanoma and PTC, 45% of ATC, 
15% of CRC, 2% of NSCL C and less commonl y in several other tumor t ypes (based on data 
from SEER database, seer.can cer.gov) . BRAF mutations drive constitutive MAPK pathway  
activation and in turn proliferation with enhanced cellular survival. Small molecule BRAF 
inhibitors block mutant BRAF, MAPK signaling, proliferation and survival in some BRAF 
V600 -
mutant tumor cells, effects that are enhanced by  [CONTACT_693755]. To 
date, there are 3 BRAF inhibitor/MEK inhibitor combinations approved for select BRAF 
V600 -mutant cancers: dabrafenib/trametinib (melanoma, NSCL C and ATC), 
vemurafenib/cobimetinib (melanoma) and encorafenib/binimetinib (melanoma). 
Metastatic spread to the CNS is a particularl y poor prognostic factor for many solid cancers, 
with average survival t ypi[INVESTIGATOR_897]  <[ADDRESS_940946] risks of spread to the CNS, with lifetime prevalences of 40 -60% 
and 20
-40%, respectivel y.2,3,4
Due to poor brain penetration and limited intracranial activity in earl y clinical trials, 
randomized studies of approved BRAF/MEK inhibitors in patients with melanoma and 
NSCL C (the frequency  of brain metastases in CRC and ATC is low) excluded patients with 
untreated (ie, with local brain therap y), symptomatic (including a requirement for steroids 
and anti -epi[INVESTIGATOR_392763] y to control symptoms) and/or progressing brain metastases.5,6,7
Recent studies of BRAF /MEK inhibitor combination therapy  in patients with solid tumor 
malignancies with brain metastases therapi[INVESTIGATOR_159358] y ielded intracranial response rates of 
between 41- 75% in as ymptomatic patients and 44 -59% in sy mptomatic patients, with 
duration of response ranging from a median 12 months in patients with treated brain 
metastases to 4.5 months in patients with sy mptomatic brain metastases.5,6,8,9The addition of 
immunotherapy to these combinations y ielded response rates of 54 and 59% (including 29% 
intracranial CR), with median intracranial and overall DoR not reached (12 month landmark 
global PFS was 56.6%).10Patients with BRAF V600- mutant melanoma and NSCL C with 
metastases to the brain ,therefore, usuall y receive local brain therap y (eg, SRS, surgical 
resection, WBRT) at some point during their disease course. SRS and surgery  are generally  
limited to 3 or fewer lesions (SRS) or a single large (>3 cm) or posterior fossa lesion 
(surgery ) and do not control disease at untreated sites. WBRT causes accelerat ed cognitive 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 20decline and was no better than supportive care in NSCL C patients.11There is therefore an 
unmet need to identify  new treatment approache s that target BRAF V600 -mutant cancers 
both sy stemicall y and in the brain.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology  of PF -07284890 can be found in the current IB.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
After oral administration, plasma exposures of PF- 07284890 (AUC and C max) increased with 
dose in all species and the absolute oral bioavailability  was moderate to complete. GL P TK 
studies in the rat (doses of 10, 30 and 60 mg/kg) and monkey  (doses of 10, 30 and 100 
mg/kg) showed l ess than dose -proportional exposures, as might be expected based on 
relativel y low aqueous solubility  (ie, in simulated gastric fluid at 37oC at a pH of 1.2, 131.6 
μg/mL , and in fasted state simulated intestinal fluid at a pH of 6.5, 7.6 μg/mL ).
In vitro and in vivo metabolite identification suggested that PF -07284890 was metabolized 
through multiple oxidative and/or glucuronos yltransferase enzy mes. Comparisons of across 
species suggested that direct N -glucuronidation is predicted to be the predominant metabolic 
route in humans. PF
-07284890 glucuronidation is the primary  route of metabolism in human 
hepatocy tes with minor contribution from CYP3A4 and aldehy de oxidase. An in vitro study  
conducted to characterize the involvement of 11 selected human UGTs isoforms in the 
metabolism of PF -07284890 indicated that UGT2B7 was the principal human isoform likely  
responsible for primary  glucuronide conjugates. Renal clearance was a minor elimination 
route of unchanged PF -07284890 in rats (<1% of an IV dose) and is predicted to be a minor 
route across all species, including humans.
Additional information of the nonclinical PKand metabolism of PF -07321332 is available in 
the current IB.
2.2.3. Nonclinical Safety
Safety  pharmacology  studies were conducted in rats and monkey s to assess the effects of 
PF-07284890 on key  organ sy stems (cardiovascular, respi[INVESTIGATOR_696] , neurobehavioral and 
gastrointestinal function). Rats and monkey s received single oral doses of up to 100
 mg/kg 
PF-
07284890 . There were no significant in vivo safet y pharmacology findings seen in either 
species. Additionally , PF- 07284890 was evaluated at concentrations up to 100 µM in the in 
vitro GL P hERG channel assay  and showed an IC 50of 70.15 
M.
The toxi cological evaluation of PF-07284890 included: 28 -day repeat -dose studies in 
Sprague Dawley  rats and cy
nomolgus monkey s, a genotoxicity  assay  (Ames), a local 
tolerance stud y (GI irritation in the rat) and an in vitro phototoxicity  study . All of these 
studie s were conducted in accordance with international regulatory  guidelines for nonclinical 
toxicity  studies and in adherence to current GLP guidelines. 
Following 28 day s of once -daily oral administration of PF-07284890 (10, 30 or 60 mg/kg) to 
Sprague Dawley  rats, the toxicological response was characterized primarily b y the clinical 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 21observations of hindlimb swelling, requiring euthanasia of 6 (out of 150) rats, and mild 
clinical pathology  changes (decreased ALP, decreased red cell parameters, increased 
reticulocy tes, increased white cell parameters, increased a PTT and increased urine volumes); 
all of which resolved in the recovery  animals. I t is important to note that many  of the 
PF-[ADDRESS_940947] blistering, swelling and scab/crust 
formation on the hindlimbs, however, in all but the 6 animals that were euthanized the 
findings resolved or were of reduced severity  and incidence with continued dosing. 
Target org
ans in the study were testes, epi[INVESTIGATOR_587107] , heart, and skin. Organ weight decreases 
in epi[INVESTIGATOR_409739] 60 mg/kg, increases in heart at 30 and/or 60 mg/kg dose in females, and 
increases in liver, ovaries, and spleen in males and/or females were noted at all dose levels. 
Myxomatous degeneration of the heart valves at 30 and 60 mg/kg and degeneration of 
seminiferous tubules in the testes and debris in the lumen and decreased cellularity  of sperm 
in the epi[INVESTIGATOR_409739] 30 and 60 mg/kg were considered adverse hi stopathology  changes 
from terminal necrops y. All PF-
07284890 -related changes from terminal necrops y exhibited 
significant recovery , except for those in the testes and epi[INVESTIGATOR_409739] 30 and 60 mg/kg. 
Based on the requirement for euthanasia, due to the im
pairment of mobility and pain (due to 
paw/hind limb swelling )at the lower dose level, the NOAEL could not be determined. 
However, these skin effects were not seen in rats until Study  Day  10and a single female 
required euthanasia due to this effect. The S TD 10of 60 mg/kg was determined from test 
article -related lethality  or irreversible and life- threatening findings. The lowest dose of 10 
mg/kg corresponded to plasma AUC 24hron Study  Day  1 of 192 and517µg•hr/mLin male 
and female rats respectively , 12-32multiple over the planned clinical dose ( Table 1) based 
on comparison to the geometric mean AUC 24hrfor a 200-mg single dose (ie, based on C1D1)
as shown in 
Table 4.
Table 1. M OEs for Nonclinical Species Compared to Humans at Dose Levels of 
Inter esta
Subject area Key Findings Margin for HV 
C1D1 (AUC)Margin for HV 
C1D1 (C max)
General Tox Rat 28 -
Day Study QD oral 
10, 30, 60 m/k/d 
(473.05)Beginning on Study Day 10 skin effects with 
rash and/or paw  and hindlimb swelling all doses 
(10 mg/kg margin shown)Male = 12x
Female = 32xMale = 13x
Female = 21x
Myxomatous degeneration of heart valves, 
degeneration of seminiferous tubules of testes 
with decreased sperm in the epi[INVESTIGATOR_693738] >30 
mg/kg30 mg/kg M = 
39x
30 mg/kg F = 
74x30 mg/kg M = 35x
30 mg/kg F = 55x
NOAEL not achieved due to impairment of 
mobility from hind limb swelling and pain 
requiring euthanasia at 10 mg/kg (a single 
female rat) (10 mg/kg MOE shown)Male = 12x
Female = 32xMale = 13x
Female = 21x

PF-[ADDRESS_940948] area Key Findings Margin for HV 
C1D1 (AUC)Margin for HV 
C1D1 (C max)
STD 1060 mg/kg based on 4/32 early terminated 
animalsMale = 59x
Female = 110xMale = 41x
Female = 67x
General Tox NHP 
28-Day Study QD 
oral 10, 30, 100 
m/k/d (473.04)Well tolerated for 28 days
Minimal stomach ulceration 100 mg/kg 5x 8x
NOAEL and HNSTD 100 mg/kg 5x 8x
a.Exposures from nonclinical TK data w ere divided by [CONTACT_693756] 24hrand 
Cmaxvalues as appropriate at the 200 mg dose level (data shown in Table 4).
Following 28 day s of once -daily oral administration of PF-07284890 (10, 30 or 100 mg/kg) 
in cy nomolgus monkey s, no adverse toxicological findings were observed, and the only  
histopathologic finding was minimal stomach ulceration at the high dose corre spond
ing to a 
plasma AUC 24of 84.4 µg•hr/mL. Given the lack of adverse findings at any  dose level, the 
NOAEL and HNSTD for daily  oral dosing of PF-
07284890 in male and female cy nomolgus 
monkey s for 28 days was 100 mg/kg. 
In addition to the nonclinical investigations summarized above, there was no evidence of 
genotoxicity  from the bacterial reverse mutation assay  and no adverse effects on GI  mucosa 
in the rat GI irritation assay .
PF-
[ADDRESS_940949] phototoxic potential in the in vitro neu tral red uptake 
assay .
2.2.4. Clinical Overview
PF-07284890 is being evaluated as a single- agent and in combination with binimetinib in 
Study  C4471001.
[IP_ADDRESS]. First -in-Human Study (C4471001)
Study  C4471001 is an ongoing Phase 1a/b, open- label, multicenter study  of the safet y, PK 
and preliminary  clinical activity  of PF -
07284890 in adult participants with selected BRAF 
V600 -mutant advanced or metastatic solid tumor malignancies and primary  brain tumors. 
The study  is being conducted in 2 parts, Phase 1a(Dose Escalation) a nd Phase 1b(Dose 
Expansion and a DDI sub- study ). The Phase 1adose escalation will evaluate the safet y and 
PK of monotherap y (PF -07284890 alone) and combination therapy  (PF-07284890 plus 
binimetinib) repeat -dosing .Phase 1b dose expansion will evaluate ef ficacy , safet y, and PK at 
the MTD/RDE of the combination therapy (PF-07284890 plus binimetinib) in 5 cohorts of 
patients and a DDI Sub- Study .
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS].1. Study Design
Phase 1a – Dose Escalation
The study  plans to enroll approximately  35 adult participants with selected BRAF V600 -
mutant advanced or metastatic solid tumor malignancies and primary  brain tumors to 
determine the MTD and/or recommended dose for further stud y of PF -07284890 alone and in
combination with binimetinib 45 mg BID. As of 10 January  2022, 4 dose levels (50 mg QD, 
100 mg QD, 200 mg QD, 200 mg BID) of PF -07284890 monotherap yhad been evaluated 
and 3 dose levels of PF- 07284890 had been evaluated (100 mg QD, 100 mg BID, and 150 
mg BID) in combination with binimetinib [ADDRESS_940950] brain involvement, bu t the 
trial initially  restricted enrollment to patients with brain lesions ≤ [ADDRESS_940951] 14 days prior to the start of study  treatment. Once 
concentrations of PF- 07284890 at steady  state met or exceeded 0. 168 µg/mL in at least two-
thirds of participants at the same dose level, a level at which antitumor activity  in the brain 
and sy stemically  was expected, patients whose brain involvement was symptomatic or whose 
brain lesions exceeded [ADDRESS_940952] not require immediate local intervention 
for the treatment of brain metastases/primary  brain tumor. 
Phase 1b – Dose Expansion
After identification of the combination MTD/recommended dose for further study , 
approximately  40 participants will be enrolled to each of Cohorts 1- 4 and 20 participants to 
Cohort 5 of Phase 1bdose expansion based on tumor ty pe, symptomatic versus 
asymptomatic brain involvement, and prior treatment history .
[IP_ADDRESS].2. Clinical Safety of PF -07284890
As of 10 January  2022, the study  has dosed 22 patients in the Phase 1a Dose Escalation. 
Monotherapy:
At the 4 monotherap y dose levels assessed (50 mg QD, 100 mg QD, 200 mg QD, and 200 
mg BID), [ADDRESS_940953] been treated, 9 patients were DLT evaluable, and no patients 
experienced DLTs ( Table 2).Based on the safet y of the prior dose and the available PK dat a 
for PF -07284890 suggesting that twice daily  dosing would be needed to achieve trough 
concentrations at the fu -adj IC90, the recommendation to alter the schedule to twice dail y 
dosing was supported b y the BLRM and adopted with the next dose level studied being 
200mg BID.
Preliminary  safet y results of the 200 mg QD dose of PF -07284890 in patients resulted in 
treatment emergent adverse events of Grade 2 worsening gout related to underly ing condition 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 24(not related to PF -07284890) and sinus infection/sinusitis (not related to PF -07284890) as 
well as Grade 1 anorexia, arthritis, back pain, nausea and pain, all in 1 patient each. With 
repeat dosing of the 200 mg BID dose schedule, one patient experienced Grade 3 pneumonia, 
considered not related to study  drug. Grade 2 events, occurring in 1 patient each, were 
ejection fracture decreased considered related to the patient’s underl ying disease, fatigue, and 
oxygen saturation decreased preceding diagnosis of pneumonia, as well as maculo -papular 
rash. Dizziness, dry  skin, and benign skin lesion were reported in 1 patient each as Grade 1. 
At lower doses, the onl y severe events reported were fatal disease progression of cancer, 
suprapubic pain related to the patient’s underl ying disease, and 2 patients with Grade 3 
anemia, considered unrelated to study  treatment in 1 case, and in another patient with 
Grade 1 anemia at baseline in the setting of renal dy sfunction and iron deficiency . Data from 
repeat -dosing in patients suggests that the 200 mg d ose is well tolerated.
Table 2. PF-07284890 Monotherapy Dose Level Review and Status
PF-07284890 
DoseDLRM Summary and Decision
50 mg QD Number of participants reviewed: 2
Number of DLTs observed: 0
Escalate to 100 mg QD
100 mg QD Number of participants reviewed: 4, 2 DLT evaluable 
Number of DLTs observed: 0
Escalate to 200 mg QD
200 mg QD Number of participants reviewed: 3 
Number of DLTs observed: 0
Escalate to 200 mg BID
200 mg BID Number of participants reviewed: 3, 2 DLT evaluable
Number of DLTs observed: 0
Escalate to 300 mg BID
DLT evaluable: In the absence of a dose- limiting toxicity (DLT) a participant must receive ≥ 75% of their 
planned dose during the DLT observation period, which is the first cycle of treatment, a 21 -day cycle.
Combination:
Within the combination therap y dose escalation, [ADDRESS_940954] dose level (PF- 07284890 100 mg QD + binimetinib 45 mg 
BID), one patient of 4 evaluable experienced DLTs of Grade 3 creatine phosphokinase 
increased and Grade 3 h ypertension, considered related to binimetinib. Based on the safety  of 
the prior dose and the available PK data for PF -07284890 suggesting that twice dail y dosing 
would be needed to achieve trough concentrations at the fu -adj IC 90, the recommendation to 
alter the schedule to twice daily  dosing was supported b y the BLRM and adopted with the 
next dose level studied being 100 mg BID. No DLTs were observed at the 100 mg BID or 
150 mg BID levels ( Table 3). 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. S ummary of PF-07284890 Pharmacokinetics in Human
Single and repeat dose PK data from study C4471001 formonotherap y (Table 4) and for 
combination therap y when coadministered with binimetinib ( Table 5)have been obtained
under fasted conditions. PF -07284890 plasma exposure increased in a less than dose 
proportional manner. For monotherap y, the geometric mean dose -normalized AUC 24hrfor the 
200 mg QD dose was approximately  1.83- and 1.4 3-fold higher than for the 50- mgdose on 
C1D1 and C1D15, respectively , when a 4-fold increase would be expected for linear PK. The 
Tmaxranged from 1.5 to 6.0 hours across dose groups. The median t½across dose groups 
ranged from 5.
7to 10 hours .PF-07284890 exposures were somewhat higher for combination 
therap y than for monotherap y, with the difference attributable to PK variability .
The accumulation ratio based on AUC values , RAUC, for patients administered PF -07284890 
QD ranged from 0.709 to 1. 31, suggesting limited accumulation for QD administration. For 
BID administration, the limited available data indicate more accumulation occurs, with an 
RAUCvalue of 1.
69for the 100 mg BID combination therap y cohort.
Table 4. PF- 07284890 Plasma PK Parameters Observed During Monotherapy 
Dose Escalation in C4471001a
PF
-07284890 
Dose and 
Regim enCycle and 
Day (N)Cmax, 
ng/mLTmax, hr AUC , 
ng hr/mLCtrough , 
ng/mLbt½, hr RCmax RAUC
50 mg QD C1D1 (2) 795 1.5 8850  6.17c 
C1D15 (2) 1440 1.5 [ZIP_CODE] 166 10.0 1.79 1.31
100 mg QD C1D1 (4) 1610 (40.3) 5.0 [ZIP_CODE] (40.5)  5.83  
C1D15 (3)1090 (16.2) 4.0 [ZIP_CODE] (8.34) 115 (71.7) 9.11 0.703 
(37.1)0.709 
(45.2)Table 3.PF-07284890 Combination with Binimetinib (45 mg BID) Dose Level 
Review and Status
PF-07284890 Dose DLRM Summary and Decision
100 mg QD Number of participants reviewed: 4
Number of DLTs observed: 1
Escalate to 100 mg BID
100 mg BID Number of participants reviewed: 4, 3 DLT evaluable 
Number of DLTs observed: 0
Escalate to 150 mg BID
150 mg BID Number of participants reviewed: 2 
Number of DLTs obs erved: 0
Escalate to 225 mg BID
DLT evaluable: In the absence of a dose- limiting toxicity (DLT) a participant must receive ≥ 75% of their 
planned dose during the DLT observation period, which is the first cycle of treatment, a 21 -day cycle.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 26Table 4. PF- 07284890 Plasma PK Parameters Observed During Monotherapy 
Dose Escalation in C4471001a
PF
-07284890 
Dose and 
Regim enCycle and 
Day (N)Cmax, 
ng/mLTmax, hr AUC , 
ng hr/mLCtrough , 
ng/mLbt½, hr RCmax RAUC
200 mg QD C1D1 (3) 1580 (20.3) 6.0 [ZIP_CODE] (22.5)  5.68  
C1D15 (3)1820 (15.5) 2.0 [ZIP_CODE] ( 8.12 )116 (329) 9.64 1.15 
(36.6)1.02
(14.3)
200 mg BID C1D1 (3) 1890 (39.2) 6.0 17000d   
C1D15 ND ND ND ND ND ND ND
a.Analysis includes bioanalytical data available through 21DEC2021 , and results are preliminary data that 
did not use the actual sample times . Values are Geometric mean (geometric %CV) except for when N 
<3, for w hich median values are presented, and for T maxand t½, where median is presented. ND = no 
data.
b.Ctrough is the Cp value pre -dose on C1D15.
c. Only could be determined for [ADDRESS_940955].
d.Only could be determined for 2 subjects.
Table 5.PF-07284890 Plasma PK Parameters Observed During Combination Dose 
Escalation in C4471001a
PF-07284890 
Dose and 
Regim en(N)Cycle and 
Day (N)Cmax, 
ng/mLTmax, hr AUC , 
ng hr/mLCtrough , 
ng/mLbt½, hr RCmax RAUC
100 mg QD C1D1 (4) 1700 (59.0) 3.5 [ZIP_CODE] (94.7)  10.3c 
C1D15 (3) 1710 (77.2) 4.0 [ZIP_CODE] 
(38.6)c166 (53.8) 7.09 1.16 (119) 1.09 
(73.9)
100 mg BID C1D1 (4) 1810 (62.7) 4.0 [ZIP_CODE] 
(72.8)c   
C1D15 (4) 2170 (34.4) 2.0 [ZIP_CODE] (42.0)761 (67.2)  1.20 
(55.1)1.69 
(31.0)c
150 mg BID C1D1 (2) 2790 4.0 [ZIP_CODE]    
C1D15 (0) ND ND ND ND ND ND ND
a.Analysis includes bioanalytical data available through 21DEC2021 , and results are preliminary data that 
did not use the actual sample times . Values are Geometric mean (geometric %CV) except for when N 
<3, for w hich median values are presented, and for T maxand t½, where median is presented. ND = no 
data.
b.Ctrough is the Cp value pre -dose on C1D15.
c.Only could be determined for 3 subjects.
2.3.Benefit/Risk Assessment
PF-07284890 is not expected to provide an y clinical benefit to health y participants. This 
study  is designed primarily  to generate safet y, tolerability , and PK data for PF -07284890 
administered in the fasted and fed state for further clinical development.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07284890 may be found in the IB, which is the SRSD for this study .

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 272.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-07284890
Potential risks associated with PF -
07284890 include the following: GI 
irritation, skin toxicity, phototoxicity, 
heart valve ultrastructural changes, 
hyperplasia of several tissues including 
the GI tract, increased urine volume, 
decreased testicular size an d 
oligospermia, mild decrease in red blood 
cell count, mild increase in white blood 
cell count, increased heart rate and 
vascular inflammation.
Potential risks associated with other 
approved BRAF inhibitors include the 
following: feeling tired , eye effects
(including pain, redness, light sensitivity 
and/or vision loss ), rash, nausea that 
could lead to vomiting , painful joints , 
new or grow ing cancers on the skin and 
in the body , birth deformities or fetal 
death from effects on a developi[INVESTIGATOR_16103] 
(only observ ed in animals to date) , 
changes in how  electrical impulses are 
conducted in the heart which may 
increase the risk of an irregular heartbeat , 
bleeding including in the gastrointestinal 
tract, skin reaction which could be 
severe , liver toxicity , cardiomyopat hy. The potential risks are based on nonclinical toxicology 
studies in the rat and monkey. GI irritation (minimal stomach 
ulcerations) occurred in the 28 -day monkey  study and it was 
reversible. Structural changes in the heart valves (resulting in 
thickening of the valve leaflets) w as seen in the 28 -day rat 
study with near complete resolution after a non -dosing 
recovery period. Skin toxicity (sw elling, blisters, scabs) was 
seen in rat hind paws and was reversible. Adverse effects on 
male rat reproductive organs (testicular atrophy/degeneration 
and hypospermia) of up to marked severity were seen and 
these were not completely reversible after a 28 -day non-
dosing recovery perio d. Also, in the rat only: minimal to 
mild decreases in RBC, Hgb and Hct; minimal increases in 
WBC, neutrophils and eosinophils and mild increases in 
aPTT were observed and were reversible.
Preliminary safety data from the ongoing clinical trial show  
a majority of adverse events observed w ith monotherapy 
administration are low grade and consistent with the adverse 
event profile of BRAF inhibitors in a BRAF mutant 
advanced cancer populati on.Prelim inary safety results of the 
200 mg QD continuous dosing of PF -07284890 in patients 
resulted in treatment emergent adverse events of Grade 2 
worsening gout related to underlying condition and sinus 
infection/sinusitis as well as Grade [ADDRESS_940956] been selected to ensure 
that only appropriate participants are included in 
the study (see Section 5).
AEsand clinical laboratory results will be 
monitored on an ongoing basis.
A complete blood count will be performed to 
monitor for any changes in hematology 
parameters (eg, RBC, Hgb , Hct , WBC, 
neutrophils, eosinophils ). 
Coagulation testing will be performed to 
monitor for any changes in aPTT .
Physical exams will be performed to assess 
overall status including skin checks to monitor 
for AEs of the skin.
Ophthalmic exam if ocular AEs are observed .
ECGs will be performed to monitor for changes 
incardiac rhythms.
Maintaining sufficient margins of exposure 
betw een the rat and human (ie, 35-fold, see 
Table 1) is thought to mitigat
e riskassociated 
with the heart and testicular findings .

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 282.3.2. Benefit Assessment
PF-07284890 will not provide an y clinical benefit to healthy participants in this study . Any 
anticipated benefit to participants would be in terms of contribution to the process of 
developi[INVESTIGATOR_007] a new therapy in an area of unmet medical need .
2.3.3. Overall Benefit /Risk Conclusion
PF-07284890 is not expected to provide an y clinical benefit to health y participants in this 
study . Taking into account the measures taken to minimize risk to study  participants, the 
potential risks identified in association with PF -07284890 are justified by  [CONTACT_647615], in terms of contr
ibution to the process of developi[INVESTIGATOR_007] a new therapy  in an area of 
unmet medical need .
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Primary : Primary : 
To evaluate the effect of a low- fat meal on the 
exposures of PF -07284890 following a single oral 
200-mgdose
To evaluate the effect of a high -fat meal on the 
exposures of PF -07284890 following a single oral 
200-mg doseComparison of low -fat meal with fasted PK: The ratio of 
AUC last, AUC inf(if data permit) and C maxof 
PF-07284890
Comparison of high -fat meal with fasted PK: The ratio 
of AUC last, AUC inf(if data permit) and C maxof 
PF-07284890
Secondary: Secondary : 
To characterize the pharmacokinetic parameters of 
PF-07284890 following a single oral 200-mg doseTmax, t½, CL/F and V z/F (if data permit).
To evaluate the safety and tolerability of PF-07284890 
in healthy participantsAssessment of TEAEs, clinical laboratory abnormalities, 
vital signs, and [ADDRESS_940957] of 3 treatments: a single oral dose of 200 
mg PF -07284890 (2 × 100 mg tablets) under fasted conditions (Treatment A , Reference ), a 
single oral dose of 200 mg PF -
07284890 (2 × 100 mg tablets) under low- fat meal fed 
conditions (Treatment B , Test 1 ), and a single oral dose of 200 mg PF -07284890 (2 × 100 mg 
tablets) under high -fat meal fed conditions (Treatment C , Test 2). There will be a total of 2 
treatment sequences shown in Section 1.2 with the assigned Treatments A ,B or C in each 
treatment period.
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 29Approximately  12 healthy  participants will be randomly  assigned to study  intervention such 
that approximately  6 participants wi ll be enrolled to each sequence . Participants who 
discontinue from the study for non -safet y reasons may be replaced at the sponsor’s discretion 
in collaboration with the investigator.
Health y participants will be screened to determine eligibility  within 28 days prior to study  
treatment. Medical history and results of ph ysical examination, phy sical measurements, vital 
signs, 12 -lead ECGs, and clinical laboratory  evaluations will determine eligibility .
Each enrolled participant will participate in 3 study per iods to receive 3 different treatments 
according to the sequence determined b y randomization with 5-daywashouts between 
PF-07284890 administration : 
Treatment A: Single oral dose of 200 mg PF
-07284890 (2 × 100 mg tablets) under fasted 
conditions (Referenc e).
Treatment B: Single oral dose of 200 mg PF -07284890 (2 × 100 mg tablets) under fed 
conditions, low -fat meal (Test 1) .
Treatment C: Single oral dose of 200 mg PF -07284890 (2 × 100 mg tablets) under fed 
conditions, high -fat meal (Test 2) .
Participants wi ll be randomly  assigned to [ADDRESS_940958] 12 hours prior to the dosing of 
PF-07284890 on Day  1. On the morning of Day  1 of each period, participants will receive a 
single dose of 200 mg PF-07284890 as per randomization schedule . Study  intervention will 
be administered with approximately  240 mL of ambient temperature water. In the fasted 
period ( Sequence 1 Period 1 and Sequence 2 Period 2), participants will get their first dose 
after an overnight fast of at least 10 hours. In fed periods 
(Sequence 2 Period 1 and Sequence 
1 Period 2 for the low - fat meal and Period 3 for the high- fat meal as shown in Section 1.2), 
following an overnight fast of at least [ADDRESS_940959] 
approx imately  30 minutes prior to PF -07284890 administration. For Sequence 2 Period 1 and 
Sequence 1 
Period 2, a low -fat (approximately  25% of total caloric content of the meal), low -
calorie (approximately  400 to 500 calories) breakfast will be consumed over app roximately  a 
20-minute interval with PF -07284890 administered within approximately  10 minutes of 
completion of the meal. For Period 3, a high -fat (approximately  50% of total caloric content 
of the meal), high -calorie (approximately  800 to 1000 calories) br eakfast will be consumed 
over approximately  a [ADDRESS_940960] dose for all periods . Period 2 will begin on S tudy Period 1, Day 5(referred 
to as Period 2, Day  -1). Period 3 will begin on Study  Period 2, Day  5 (referred to as Period 3, 
Day -1). Participants will be discharged from the CRU at the end of Period 3, Study  Day 4, 
following completion of all assessments.
After p articipants have been 
confined in the CRU , they  will be discharged at the discretion of 
the investigator. If a participant has an y clinically significant, stud y related abnormalities at 
the conclusion of a scheduled inpatient portion of the study , the [COMPANY_007] medical monitor (or 
designated representative) should be notified and the participant may  be asked to remain in 
the CRU until such abnormalities are deemed not clinically  significant, or it is safe for 
outpatient follow up. A safet y follow -up call will be made to participants [ADDRESS_940961] of a low -fat or high -fat meal on the 
relative bioavailabilit y of PF -07284890 following single 200-mg dose oral administration 
using a 100 mg tablet formulation of PF -07284890 in healthy  adult participant s.A crossover 
design is used to control variability
 between participants and account for any  period 
effects.Between each administered single dose, a 5-day washout is proposed to minimize any  
residual PF -
07284890 concentrations prior to start of the next p eriod, which is sufficient 
based on the observed half-life of approximately 5.7to 10 hours (Table 4).
4.2.1. Assessment of Safety Data Before Administration of the High -fat Meal
The high -fat meal is expected to potentially  increase 
exposures by [CONTACT_422906]  
2-fold .12Before the Period [ADDRESS_940962] 8 participants (given that 
participants may  not all be dosed at the same time) administered
a low -fat meal in Period [ADDRESS_940963] 
after a discussion between the study  team and the investigator. 
Period 3 will initiate as 
planned if the dose sadministered in Period s 1 and 2 werewell-tolerated. 
Severe nonserious AEs considered as related to study  intervention in 2 participants in a 
period would require a dose reduction. Any SAE considered related to study  intervention 
would require a dose reduction. Dosing will be paused for an y SAE that occurs in a 
participant receiving active treatment until causa lity is fully  assessed by  [CONTACT_978]  [INVESTIGATOR_38107]. 
Dosing may  resume if the SAE is determined to be not drug related by  [CONTACT_978]  [INVESTIGATOR_38107]. If 
the SAE is determined to be either drug related or unknown and is ≥ severe or CTCAE 
Grade 3, dosing of participants will be stopped. If the SAE is determined to be either drug 
related or unknown and is <severe or CTCAE Grade 3, the SAE will be evaluated by  [CONTACT_103]’s protocol review committee (or similar review group), which is independent of the 
study  team and inves tigators. If the protocol review committee determines that dosing may  
resume, a plan that mitigates risks to participants with the resumption of dosing will be 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 31implemented. Such a plan could include reducing the dose or adding appropriate safety  
monitoring .
4.2.2. Choice of Contraception/Barrier Requirements
Nonclinical studies suggest risk for severe manifestations of developmental toxicity  at 
relevant clinical exposures for PF-07284890. Therefore, the use of a highly  effective method 
of contraception is required (seeAppendix 4 ).
4.2.3. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention.
 
 
 
4.3.Justification for Dose
A single 200 mg dose of PF -07284890 is planned for each period of this study . 
Following 28 day s of once -daily oral administration of PF -
07284890 (10, 30 or 60 mg/kg) to 
Sprague Dawley  rats (the sensitive species) in a GLP toxicology  study , t he STD 10was60 
mg/kg. For the lowest dose of 10 mg/kg ,exposures in male and female rats, respectivel y,are 
estimated to be 12-32 multiple over those of the planned clinical dose (ie, see details in 
Section 2.2.3). The effect of food onPF-07284890 exposures based on its propert i es
(Biopharmaceutics Classification Sy stem Class II compound, we ak base ) isexpected to be 
less than a 2- fold increase ;12a 2-fold increase in human exposures would reduce these 
margins to be ~6 -16 multiple over those of the planned clinical dose. The clinical data from 
C4471001 
are also important for justify ing the 200 mg dose.
Clinical experience with PF
-07284890 is based on the FIH stud y, C4471001, in which 
dose-finding is being conducted based on the safety  and PK of repeat doses of PF -07284890. 
As of 10 January  2022, the study  has dosed 22 patients in the Phase 1a Dose Escalation. At 
the 4 monotherap y dose levels assessed (50 mg QD, 100 mg QD, 200 mg QD, and 200 mg 
BID), [ADDRESS_940964] been treated, 9 patients were DLT evaluable, and no patients 
experienced DLTs ( Table 2). 
Preliminary  safet y results of the 200 mg QD dose of PF -07284890 in patients resulted in 
treatment emergent adverse events of 
Grade 2 worsening gout related to underly ing condition 
and sinus infection/sinusitis as well as Grade 1 anorexia, arthritis, back pain, nausea and pain, 
all in 1 patient each. With repeat dosing of the 200 mg BID dose schedule, one patient 
experi enced Grade 3 pneumonia, considered not related to study  drug. Grade 2 events, 
occurring in 1 patient each, were ejection fracture decreased considered related to the 
patient ’s underl ying disease, fatigue, and oxy gen saturation decreased preceding diagnosi s of 
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 32pneumonia, as well as maculo -papular rash. Dizziness, dry  skin, and benign skin lesion were 
reported in 1 patient each as Grade 1. At lower doses, the only  severe events reported were 
fatal disease progression of cancer, suprapubic pain related to the patient’s underlying 
disease, and [ADDRESS_940965] tolerated dose of 200 mg BID is 
estimated to be approximately  3.4-fold higher than the AUC 24hrfor a single dose of 200 mg
(ie, based on the accumulation ratio of 
1.[ADDRESS_940966] 
approxi matel y2 x 1. 69-fold higher AUC 24hr) .Food may  increase the AUC 24hr, but this 3. 4-
fold margin based on fasted
-state PK increases confidence in the safet y of the single daily  
dose given one time every  5days for [ADDRESS_940967] y:
Age and Sex :
1.Participants ≥18 and 65years of age, inclusive, at the time of signing the ICD .
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section
10.4.2) participants.
2.Male participants and female participants of non -childbearing potential 
(Section 10.4.2) who are overtly  healthy  as determined by  [CONTACT_394984], phy sical examination, laboratory  tests, 
vital signs and 
12-lead ECGs .
Other Inclusion Criteria : 
3.BMI of 17.5 to 30 .5kg/m2; and a total body  weight >50 kg (110 lb).
4.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
5.
Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2. Exclusion Criteria
Participants are e xcluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant uveitis, hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
Any condition possibly  affecting drug absorption (eg, gastrectomy , 
cholecy stectom y).
History  of HIV infection, hepatitis B, or he patitis C; positive testing for HIV, 
HBsAg, HBcAb or HCVAb. Hepatitis B vaccination is allowed.
Use of PPI s is not allowed within 7 day s of study  start (C1D1) and during study  
treatment.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 342.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg , 
contact [CONTACT_216478], residence, 
or travel to an area with high incidence) that may  increase the risk of study 
participation or , in the investigator’s judgment, make the participant inappropriate for 
thestudy .
Prior/Concomitant Therapy:
3.Use of prescription or 
nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is lo nger) prior to the first dose of study  
intervention . (Refer to Section 6.9Prior and Concomitant Therap y for additional 
details).
4.Current use or anticipated need for drugs that are known strong UGT2B7 inhibitors,
including the administration within [ADDRESS_940968] received a COVID -19 vaccine within 7 day s before screening or 
admission, or who are to be vaccinated with a COVID -19 vaccine at any  time during 
the study  confinement period.
Prior/Concurrent Clinical Study Experience:
6.
Previous administration with an invest igational product (drug or vaccine) within 
30days (or as determined by  [CONTACT_19970]) or [ADDRESS_940969] 
dose of study  intervention used in this study  (whichever is longer). 
Diagnostic Assessments:
7.Positive test result (RT -PCR) for SARS -CoV -[ADDRESS_940970] at screening or admission.
10.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_940971]. If BP is ≥140 mmHg (s ystolic) or ≥ 90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
11.Standard 12-lead ECG thatdemonstrates clinicall yrelevant abnormalities that may  
affect participant safety or interpretation of study results (eg, QTc F450ms,
complete LBBB, signs of an acute or indeterminate- age myocardial infarction, ST -T 

PF-[ADDRESS_940972] -degree AV
block, or serious brad yarrhythmias or tach yarrhythmias). If the uncorrected QT
interval is >450 ms, this interval should be rate -corrected using the Fridericia method 
only and the resulting QTcF should be used for decision making and reporting. If 
QTcFexceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated 
twice
and the average of the 3 QTcFor QRS values used to determine the participant’s 
eligibility .Computer -interpreted ECGs should be overread by  a physician 
experienced in reading ECGs before excluding a participant.
12.Participant s with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST or ALT level ≥1.25 × ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history  of Gilbert ’s 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ ULN.
eGFR <75mL/min/1.73 m2based on the CKD -EPI [INVESTIGATOR_10908].
Hemoglobin <11 g/dL
ANC <1.5 × 109/L
Platelets < 100,000/ mm3
Other Exclusion Criteria
:
13.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spi[INVESTIGATOR_17040] ,or 3ounces (90 mL) of wine).
14.Current smokers or history  of the use of tobacco - or nicotine- containing products
within 6 months of screening.
15.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL)or 
more within 60days prior to dosing .
16.History  of sensitivity  to heparin or heparin -induced thrombocy topenia .
17.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol .

PF-[ADDRESS_940973] of the study  and their family  
members.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Contraception 
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception met hods (see Appendix 4 , 
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and
correct use. At time points indicated in SoA, the investigator or designee will inform the 
participant of the need to use highl y effective contraception consistentl y and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart. 
Participants need to affirm their consistent and correct use of at least [ADDRESS_940974] inence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
5.3.2. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least [ADDRESS_940975], followed b y pre -dose ECGs and 
PKsampling (which will be followed b y food in the fed periods, 
Sequence 2 Period 1
and Sequence 1 Period 2 f or the low -fat meal and Period 3for the high-fat meal , prior 
to dosing) .
For the fasted period ( Sequence 1 Period 1 and Sequence 2 Period 2 ), water is 
permitted until 1 hour prior to study  intervention administration. Water may  be 
consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
may be consumed with meals and the evening snack .
For the first fed period, low -fat meal ( Sequence 2 Period 1 and Sequence 1 Period 2 
for the low -fat meal ) only , a low-fat(approximately  25% of total caloric content of 
the meal), low-calorie (approximately 400 to 500 calories) meal will be used for the 
evaluation of a food effect in this study . The provided meal will be similar in 
composition to the meal referenced in the FDA guidance on food -effect 
bioavailability  and fed bioequivalence studies .15OnDay [ADDRESS_940976]. There are no water restrictions prior to 
and after dosing.
For the second fed period , high - fat meal (Period 3) only , a high- fat(approximately  
50% of total caloric content of the meal), high-calorie (approximately 800 to 1000 
calories) meal will be used for the evaluation of a food effect in this study . The 
provided meal will be similar in composition to the meal referenced in the FDA 
guidance on food -effect bioavailability  and fed bioequ
ivalence studies.15OnDay [ADDRESS_940977]. There are no 
water restrictions prior to and after dosing.
Lunch will be provided approximately  4to 5hours after dosing .
Dinner will be provided approximately  9to 10 hours after dosing
.
An evening snack may be permitted .
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
Participant swill abstain from caffeine -
containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period.
Participant s will abstain from alcohol for [ADDRESS_940978] at the 
discretion of the investigator.
Participant s will not have used tobacco -or nicotine -containing products for 6 months
prior to screening and will not use such products during the screening period or after 
confinement in the CRU.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 385.3.4. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to standardize the conditions on PK sampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
4
hours after dosing;
Participant s will be confined to the procedure room for the first [ADDRESS_940979], b y minimizing the 
participants’ exposure to light including sunlight, and high intensit y UVB light sources such 
as tanning beds, tanning booths and sunlamps. Participants should be encouraged to appl y 
sunscreen/sunblock daily and to wear clothing that covers areas of exposed skin when 
outdoors during day light hours until discharge from the CRU , which is more than [ADDRESS_940980] dose of PF -07284890.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational and noninvestigational medicinal 
products, medical devices, and other interventions (eg, surgical and behavioral) intended to 
be administered t
o the study  participants during the study  conduct . 
For the purposes of this protocol, study  intervention refers to PF-07284890.
6.1.Study Intervention(s) Administered
Study Intervention (s)
Intervention Name [INVESTIGATOR_16335]-07284890
Type Drug
Dose Formulation Tablet

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 39Study Intervention (s)
Unit Dose Strength(s) 100 mg
Dosage Level(s) 3 single 200 -mg doses
Route of Administration Oral
Use Experimental
IMP or NIMP /AxMP IMP
Sourcing Provided centrally by [CONTACT_693757] -label s tudy intervention will be provided in bulk (high -density polyethylene 
bottle ) labeled as required per country requirement.
Current/Former Name(s) 
or Alias(es)PF-[ADDRESS_940981] will be administered orall y and according to the conditions described 
in the SoA section and Protocol Section 5.3.2 Meals and Dietary  Restrictions .
For fastedperiod ( Sequence 1 Period 1 and Sequence 2 Period 2 ):
On Day  1, following an overnight fast of at least 10 hours, the participants will receive 
200mg PF - 0 7284890 (as 2 × 100 mg tablets) administered orall y at approximately  
08:00 hours (plus or minus 2 hours) without breakfast/standard meal on Day  1. 
For fed periods 
(Sequence 2 Period 1 and Sequence 1 Period 2 for the low -fat meal and 
Period 3 for the high-fat meal) : 
On Day  1, following an overnight fast of at least [ADDRESS_940982] approximately  30 minutes prior to dosing which is to be completed within
approximately  20minutes as outlined in Section 5.3.2 Meals and Dietary  Restrictions . 
The participants will then receive 200 mg PF - 07284890 (as 2 × 1 00 mg tablets) 
administered orall y at approximately 08:00 hours (plus or minus 2 hours). 
For allperiods:
Investigator site personnel will administer study  intervention during each period with 
ambient temperature water to a total volume of approximately  [ADDRESS_940983]
udy 
intervention prior to swallowing. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 40In order to standardize the conditions on PK sampling day s, all participants will be 
required to refrain from ly ing down (except when required for BP, pulse rate, and ECG 
measurements), eating, and drinking beverages other than water during the first [ADDRESS_940984] confirm that 
appropriate conditions (eg, 
temperature) have been maintained during transit for all study  intervention sreceived 
and an y discrepancies are reported and resolved before use of the stud y intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/ or administer study intervention.
3.All study  intervention must be stored in a secure, environmentally  controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented upon 
return to business
.
4.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with actions taken. The site should activel y 
pursue options for returning the stud y intervention to the labeled storage conditi ons, 
as soon as possible. Once an excursion is identified, the study  intervention must be 
quarantined and not used until [COMPANY_007] provides permission to use the study  
intervention. Specific details regarding the excursion definition and information to
report for each excursion will be provided to the site in the I PMor PCRU site 
procedures.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
6.Study  intervention should be stored in itsoriginal container.
7. The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition rec ords) , such as the I PAL  or sponsor -approved equivalent .All study  
intervention will be accounted for using a study  intervention accountability  
form/record.
8.Further guidance and information for the final disposition of unused study  
intervention are provided in the I PMandPCRU’s site procedures .All destruction 
must be adequatel y documented. If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 

PF-[ADDRESS_940985] complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I PM.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the particip antby [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider or
participant in accordance with this protocol. L ocal health a uthority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
PF-07284890 t ablets will be prepared at the CRU in the individual dosing containers by  
2operators, 1 of whom is an appropriatel y qualified and experienced member of the study  
staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  
assistant/technician, or pharmacist). The tablets will be provided in unit dose containers and 
labeled in accordance with [COMPANY_007] regulations and the clini cal site’s labeling requirements. 
See the IPM and/or CRU’s site procedures for instructions on how to prepare the study  
intervention for administration.
6.3.Assignment to Study Intervention
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . [COMPANY_007] will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the stud y treatment regimen 
assigned to the corresponding randomization number.
6.4.Blinding
This is an open -label study . 
6.5.
Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by  a second qualified member of the study  site staff.
Participants will be dosed at the site andreceive study  intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the C RF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will examine each participa nt’s mouth to ensure that 
the study  intervention was ingested.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 426.6. Dose Modification
No dose modification is anticipated. A 200- mg dose is the maximum dose that will be 
administered. Incase a dose reduction is necessary , the study  intervention dose will be 
reduced or the study  will be stopped early .
6.7.Continued Access to Study Intervention A fter the End of the Study
Nostudy intervention will be provided to participants at the end of their study  participation.
6.8.Treatment of Overdose
For this study , any  dose of PF -07284890 greater than the prescribed regimen within a 
24-hour time period ± 6hours will be considered an overdose .
Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact [CONTACT_219876] 24 hours.
2.Closely  monitor the participant for an y A
Es/SAEs and laboratory  abnormalities as 
medically  appropriate forat least 5 half -lives or 28 calendar days (whichever is 
longer) after the overdose of PF -07284890.
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 7days from t he date of the last dose of 
study  intervention if requested by  [CONTACT_219877] (determined on a 
case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_693758] m onitor as needed based on the clinical evaluation of the 
participant.
6.9.Prior and 
Concomitant Therapy
Participants will abstain from all concomitant treatments, except for the treatment of adverse
events . Use of prescription or nonprescription drugs and die tary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall resul ts of the study may  be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .

PF-[ADDRESS_940986] of 
example prohibited medications (eg, strong CYP3A inhibitors and inducers) is provided in
Section 10.9, Appendix 9: Prohibited Concomitant Medications That May  Result inDDI.
CYP3 A4/5:
Concomitant use of PF- 07284890 and a CYP3A4/5 substrate may  increase or decrease the
exposure of the CYP3A4/5 substrate. Coadministration of PF- 07284890 with CYP3A4/5
substrates with narrow therapeutic indices, such as astemizole, terfenadine, cisapr ide,
pi[INVESTIGATOR_3924], quinidine, tacrolimus, cy closporine, sirolimus, alfentanil and fentany l (excluding
transdermal patch), or ergot alkaloids (ergotamine, dihy droergotamine)16,17is not permitted.
Coadministration with other CYP3A4/5 substrates is permitted but caution is warranted.
CYP2B6:
Concomitant use of PF- 07284890 and a CYP2B6 substrate may  decrease the exposure of the
CYP2B6 substrate. PF -07284890 coadministration with CYP2B6 substrates (eg, a sensitive
substrate like bupropi[INVESTIGATOR_693739], also a
sensitive substrate, and cyclophosphamide)16,17is permitted but caution is warranted.
CYP2C9:
Concomitant use of PF- 07284890 and a CYP2C9 substrate may  increase the exposure of the
CYP2C9 substrate. CYP2C9 substrates of a narrow therapeutic index, may include warfarin,
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 44pheny toin, glimepi[INVESTIGATOR_14956], glipi[INVESTIGATOR_7130], gly buride, ibuprofen, diclofenac, indomethacin, naproxen,
rosiglitazone, sulfamethoxazole, tolbutamide, candesartan, irbesartan, losartan and
valsartan.16,18PF-07284890 coadministration with these and other CYP2C9 substrates is
permitted but caution is warranted.
BCRP:
Concomitant use of PF- 07284890 and a BCRP inhibitor or inducer may  alter the rate and/or
extent of PF -07284890 absorption, which could potentially  increase (inhibitor) or decrease
(inducer) PF- 07284890 exposures. PF -07284890 coadministration with BCRP inhibitors or
inducers is permitted but caution is warranted.
P
-glycoprotein:
Concomitant use of PF- 07284890 and a P -glycoprotein substrate may increase the exposure
of the P -glycoprotein substrate. PF -07284890 coadministration with P -glycoprotein
substrates is permitted but caution is warranted.
Acid Reducing Agents:
Concomitant use of PF- 07284890 and an acid reducing agent (eg, PPIs) may cause reduced
exposures to PF -07284890. PPI s are not allowed within 7 day s of study  start (C1D1) and
during stud y treatment, but other acid reducing agents (eg, H2 blockers, antacids) may  be
used, but only  between 2 and 3 hours after administration of each dose of PF -07284890.
6.9.1. Rescue Medicine
There is no rescue therapy to reverse the AEs observed with PF-07284890; standard medical 
supportive care must be 
provided to manage the AEs.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following :
AE requiring discontinuation in investigator’s view;
Positive COVI D-[ADDRESS_940987].
If study  intervention is permanentl ydiscontinued, the participant will not remain in the study  
for further evalu ation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 457.1.1. ECG Changes
A participant who meets either bulleted criterion based on ECG readings will be withdrawn 
from the study intervention . 
QTcF >500 ms.
Change from baseline: QTc F>60 msand QTcF >450 ms.
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QT cFafter enrollment ), the investigator or qualified designee will determine if 
the part icipant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. An y 
new clinicall y relevant finding should be reported as an AE.
7.1.2. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered import ant medical events. 
An increase of 
≥0.3 mg/dL (or ≥26.5 µ mol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [ or ≥26.5 µ mol/L ]in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µ mol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of la boratory  abnormalities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants in agiven period are noted to have 2 consecutive
SCr results of ≥0.3 mg/dL (or ≥26.5 µ mol/L ), an assessment of whether the finding may  be 
considered an adverse drug reaction should be undertaken.
7.1.3. COVID -19
If a participant has COVID -19 during the study , this s hould be reported as an AE or SAE (as 
appropriate) and appropriate medical intervention provided. Temporary  discontinuation of 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 46the study  intervention may  be medicall y appropriate until the participant has recovered from 
COVID -19. It is recommended that the investigator discuss temporary  or permanent 
discontinuation of study  intervention with the study  medical monitor. 
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study medical monitor . 
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at their own request . Reasons for 
discontinuation from the study  include the following :
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  terminated by  [CONTACT_3211];
Investigator’s decision;
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of stu dy 
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early discontinuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal. 
The participant will be permanentl y discontinued from the study intervention and the study  at 
that time.
If a participant withdraws from the study , they may request destruction of any  remaining 
samples tak
en and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use an y data 
collected before such 
withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any  further contact 
[CONTACT_185609]. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 47Participant s should notify  the investigator in writing of the decision to withdraw consent 
from fu ture follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or posttreatment study  
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly  available information should be 
used to determine vital status only  as appropriately  directed in accordance with local law.
7.3.Lost to Follow -up 
A participant will be considered lost to follow- up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066].
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continu e to be unreachable, the participant will be considered 
to have withdrawn from the study . 
8.STUDY ASSESSMENTS AND PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurr ence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 

PF-[ADDRESS_940988] details of all participants screened and to confirm eligibility  or recor d reasons for 
screening failure, as applicable.
Participant s will be screened within 28 days prior to administration of the study  intervention
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
Every  effort should be made to ensur e that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions th at they have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_693759] .
The total blood sampling volume for individual participant s in this study  is approximately  
210mL.The actual collection times of blood sampling may
 change. Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study does not exceed 550 mLduring an y period of 56 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.2.Efficacy Assessments
Not applicable.
8.3.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled safety
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 498.3.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, asse ssments of general appearance, 
skin, the respi[INVESTIGATOR_2866] s ystems, and participant -reported sy mptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician ’s assistant, or 
nurse practitioner as acceptable according to loca l regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. 
Participant s must remove shoes, bulk y layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to 8.4.3.
8.3.2. Vital Signs
[IP_ADDRESS]. Blood Pressure and Pulse Rate
Supi[INVESTIGATOR_693740] ’s arm supported at the level of the 
heart and recorded to the nearest mm Hgafter approximate ly 5minutes of rest . The same 
arm (preferabl y the dominant arm) will be used throughout the stud y.Participant s should be 
instructed not to speak during measurements. BP and PR assessments will be performed after 
collection of ECGs and prior to collection of blood draws if scheduled at the same time.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary
, to ensure appropriate collection of safety  data. If the pulse rate is 
outside of the normal limits, respi[INVESTIGATOR_693741].
Any untoward vital sig n findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 
8.4.1 to 8.4.3.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Respi[INVESTIGATOR_693742]. Respi[INVESTIGATOR_693743]  5minutes of rest in a supi[INVESTIGATOR_693744] [ADDRESS_940989] yingby 2. 
[IP_ADDRESS]. Temperature
Temperature will be measured orall y. No eating, dri nking, or smoking is allowed for 
[ADDRESS_940990] 12-l ead E CGs utilizing limb leads (with a 10- second rhy thm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the HR and measures PR interval , QT interval , QTc F,and QRS 
complex . Alternative lead placement methodology using torso leads (eg ,Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supi[INVESTIGATOR_2547]. 
Triplicate 12 -lead ECGs will be obtained approximately  2 to 4 minutes apart; the average of 
the triplicate ECG measurements collected before dose administration on Day 1 of each 
period and before the meal for Sequence 1 Period 2,Sequence 2 Period 1, and Period 3 will 
serve as each participant ’s baseline QTc Fvalue.
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) the mean 
value from the triplicate measurements for an y postdose QTc Finterval is increased by  
≥60msfrom the baseline andis >450 ms; or b) an absolute QT value is ≥500msfor an y 
scheduled ECG. If either of these conditions occurs, then a single ECG measurement must be 
repeated at least hourly until QTc Fvalues from 2 successive ECGs fall below the threshold 
value that triggered the repeat measurement .
If a) a postdose QTc Finterval remains ≥60msfrom the baseline andis >450 ms; or b) an 
absolute QT value is ≥500msfor an y scheduled ECG for greater than 4 hours (or sooner ,at 
the discretion of the investigator) ;or c) QTcFvalue get progressively  longer, the participant
should undergo continuous ECG monitoring. A cardiologist s hould be consulted if QTcF
values do not return to less than the criteri alisted above after 8 hours of monitoring (or 
sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be nec essary  if a 
qualified medical provider
’s interpretation determines that the QTcF values are in the 
acceptable range.

PF-[ADDRESS_940991] if 
treatment emergent 
ocular AEs are observed (SoA) including best corrected visual acuity , slit lamp examination, 
andintraocular pressure.
For participants with clinical suspi[INVESTIGATOR_693745] y 
conduct (ie, photopsia, metamorphopsia, impairment of visual acuity ) or RVO, additional 
assessments of OCT, dilated fundoscopy , optical coherence tomograph y (for RPED) ,and 
fluorescein angiograph y of the central 30 degrees (for RVO) should be conducted if deemed 
clinically  necessary .
8.3.5. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_940992] findings are those that are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259] ’s condition.
All laboratory  tests with values considered clinically  significant and abnormal during 
participation in the study  or within [ADDRESS_940993] dose of stud y intervention should 
be repeat ed until the values return to normal or baseline or are no longer considered clinicall y 
significant b y the investigator or 
study  medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
DILI .
See Appendix [ADDRESS_940994] abnormalities.
Urine drug and cotinine (mandatory ) and alcohol breath test (at discretion of investigator) 
will be performed at screening from Day s -[ADDRESS_940995] will be performed after 4 day s (ie,upon completion of 4 
× 24 
hours in house), or if they develop COVID -19-like sy mptoms. Additional testing may  be 
required b y local regulations and guidance or by  [CONTACT_978] .
8.4.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant
’s legally  
authorized representative), or they  may  arise from clinical findings of the i nvestigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for clas sification as an SAE or caused the participant to discontinue 
thestudy (seeSection 7.1 ). 
During the active collection period as described in Section 8.4.1, e ach participant will be 
questioned about the occurrence of A Es in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting A Es and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before undergoing an y stud y-related procedure and/or receiving study  
intervention ), through and including a minimum of [ADDRESS_940996] SAE Report Form .
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.[ADDRESS_940997] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24hours of it s being available.
[IP_ADDRESS]. Recording Nonserious A Es and SAEs on the CRF
All nonserious AE s and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_940998] to the CRF 
requirements as described in Section 5.4.
8.4.2.
Method of Detecting AE s and SAEs
The method of recording, evaluating, and assessing causality  of A Esand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce 
bias when detecting A Es and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 548.4.3. Follow -Up of A Es and SAEs
After the initial AE or SAE report, the investigator is required to proa ctively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is provi dedin Appendix 3.
8.4.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Br eastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include EDP, EDB , and occupational exposure.
Any such e xposure s to the study  interventio nunder study  are reportable to [COMPANY_007] Safety  
within 24 hours of investigator awareness.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A male participant who is receiving or has discontinued study  intervention
inseminates a female partner .
A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure. Below are 
examples of environmental EDP:
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262], inhalation, or skin 
contact.
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  [CONTACT_78262] , inhalation or skin contact [CONTACT_336270].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant’s partner, the investigator must report this information 
to [COMPANY_007] Safety  on the CT SAE Report Form and an EDP Supplemental Form, 
regardless of whether an SAE has occurred. Details of the pregnancy  will be collected 
after the start of stud y intervention and until [ADDRESS_940999] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
inform ation to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP S upplemental F
orm. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, th e 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the f indings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 56demise, neonatal death, or congenital anomal y in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontan
eous abortion includ ingmiscarriage and missed abortion should be reported 
as an SAE ;
Neonatal deaths that occur within [ADDRESS_941000] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported a s 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case-by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The in vestigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female 
nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study  intervention (ie, environmental exposure). An example of 
environmental EDB is a female famil y member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study  intervention by  
[CONTACT_22837] .
The investigator must report EDB to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, 
the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
An EDB report is not created when a [COMPANY_007] drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accord ance with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB .

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Occupational Exposure
The investigator must repor t any instance of occupational exposure to [COMPANY_007] Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.4.6.
Cardiovascular and Death Events
Not applicable.
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AE s 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detecti on processes. Should an aggregate analy sis indicate that 
these prespecified events occur more frequentl y than expected, eg, based on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with 
[COMPANY_007]’s safet y reporting requirements. Aggregate anal yses of safet y data will be performed 
on a regular basis per internal SOP.
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.4.[ADDRESS_941001] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.4.9. Medical Device Deficiencies
Not applicable.
8.4.10. Medication Errors
Medication errors may  result from the administration or consumption of the 
study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 58Medication errors are recorded and reported as follows:
Recorded on the 
Medicati on Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly  if associated with an 
SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
In the event of a medication dosing error, the sponsor should be notified within [ADDRESS_941002] SAE Report 
Form only when associated with an SAE.
8.5.Pharmacokinetics 
8.5.1. Plasma for Analysis of PF -07284890
Bloodsamples of approximately  3mL, to provide a minimum of 1.2 mLplasma , will be 
collected for measurement of plasma concentrations of PF-
07284890 as specified in the SoA.
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual or by  [CONTACT_456]. The actual date and time (24 -hour clock time) of each 
sample will be recorded.
The actual times may  change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 - minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF . Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 59the source document and theCRF . This protocol deviation window does not apply  to samples 
to be collected more than 10 hours after dose 
administration at outpatient/follow -up visits 
with visit windows.
Samples will be used to evaluate the PK of PF-07284890 . Samples collected for anal yses of 
plasma PF-07284890 concentration may  also be used to evaluate safet y or efficacy  aspects 
related to concerns arising during or after the study, for metabolite identification and/or 
evaluation of the bioanalytical method, or for other internal exploratory  purposes.
Genetic anal yses will not be performed on these plasma samples 
unless consent for this was 
included in the informed consent. Participant confidentiality  will be maintained.
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_941003] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handli ng procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether samp le 
integrit y has been compromised.
Any changes in the timing or addition of time points for any  planned stud y assessments must 
be documented and approved by  [CONTACT_185618], but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
8.6.Genetics
8.6.1. Specified Genetics
Specified g enetic anal yses are not evaluated in this study .
 
 
 
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 60 
 
 
 
 
8.7.Biomarkers
Biomarkers are not evaluated in this study .
8.7.1. Specified Gene Expression (RNA) Research
Specified gene expression (RNA) research is not included in this study .
8.7.2. Specified Protein Research
Specified protein research is not included in this study .
8.7.3. Specified Metabolomic Research
Specified metabolomic research is not included in this study .
8.8.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.9.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in the SAP, which will be maintained by  [CONTACT_456]. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
No statistical hy pothesis will be tested in this study . 
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 619.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis 
SetDescription
Enrolled “Enrolled ”means a participant ’s agreement to participate in a 
clinical study  following completion of the informed consent 
process andassignment to study  intervention . A participant 
will be considered enrolled if the informed consent is not 
withdrawn prior to participating in an y stud y activity  after 
screening. 
Potential participan ts who are screened for the 
purpose of determining eligibility  for the stud y, but do not 
participate in the stud y, are not considered enrolled, unless 
otherwise specified b y the protocol.
Safety analysis set All participants assigned to study  intervention and who take at 
least [ADDRESS_941004] can be reported .
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. Primary Endpoint(s) Analysis
[IP_ADDRESS]. Definition of Endpoint(s)
Plasma PK parameters of PF-07284890 will be derived (as data permit) from the 
concentration -time data using standard noncompartmental methods of anal ysis as outlined in 
Table 6. Actual PK sampling times will be used in the derivation of PF-07284890 PK 
parameters when available . In the case that actual PK sampling times are not available, 
nominal PK sampling time will be used in the derivation of PK parameters. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 62Table 6. Plasma PF - 07284890 PK Parameters Definitions 
Param eter Definition Method of Determ ination
AUC inf* Area under the plasma concentration -time curve 
from time zero extrapolated to infinityAUC last+ (C last*/k el),
where C last* is the predicted plasma 
concentration at the last quantifiable 
time point from the log -linear 
regression analysis
AUC last Area under the plasma concentration -time profile 
from time zero to the time of the last quantifiable 
concentration (C last).Linear/Log trapezoidal method.
Cmax Maximum observed plasma concentration Observed directly from data
Tmax Time to reach Cmax Observed directly from data as time of 
first occurrence
t½* Term inal elimination half-life Log e(2)/k el,
where k elis the terminal phase rate 
constant calculated by a linear 
regression of the loglinear 
concentration -time curve. Only those 
data points judged to describe the 
terminal loglinear decline will be used 
in the regression.
CL/F* Apparent clearance Dose/AUC inf
Vz/F* Apparent volume of distribution for extravascular 
dosingDose/(AUC inf• kel)
*If data permit.
[IP_ADDRESS]. S tatistical Methods for Pharmacokinetic Data
Using data from Periods 1 and 2, natural log transformed AUC inf(if data permit), AUC lastand 
Cmaxwill be analy zed using a mixed effect model with sequence, period and treatment as 
fixed effects and participant within sequence as a random effect. Estimates of the adjusted 
mean differences (Test -Reference) and corresponding 90% CIs will be obtained fro m the 
model. The adjusted mean differences and 90% CIs for the differences will be exponentiated 
to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI 
for the ratios. Treatment A (PF- 07284890 under fasted condition) is t he Reference treatment 
and Treatment B (PF- 07284890 administered under fed condition, low -fat meal) is the Test 
treatment.
Using data from Treatments A and C, natural log transformed AUC inf(if data permit), 
AUC lastand C maxwill be anal yzed using a mixed effect model with treatment and sequence as 
a fixed effect and participant within sequence as a random effect. Estimates of the adjusted 
mean differences (Test -Reference) and corresponding 90% CIs will be obtained from the 
model. The adjusted mean differences and 90% CIs for the differences will be exponentiated 
to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI 
for the ratios. Treatment A (PF- 07284890 under fasted condition) is the Refe rence treatment 
and Treatment C (PF- 07284890 administered under fed condition, high-fat meal) is the Test 
treatment.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 63The plasma concentrations of PF-07284890 will be listed and descriptivel y summarized by  
[CONTACT_273480]. Individual 
participant and summary  profiles (mean 
and median plots) of the plasma concentration -time data will be plotted by  [CONTACT_693760] ,respectivel y. Mean and median profiles will be presented on both 
linear and semi -log scales. 
The PK parameters listed in Table 6will be summarized descriptivel y by [CONTACT_3148].
Additional specifications about the tables, listings, and figures will be outlined in the S AP.
9.3.2. Other Safety Analyses
All safet y anal yses will be performed on the s afety analysis set .
Safety  data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Safety  data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information, as 
applicable, collected during the course of the study, will be considered source data and will 
not be required to be reported, unless otherwise noted. However, an y untoward findings 
identified on phy sical and/or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported.
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters HR, QTc F, PR interval, and QRS complex
will be summarized by  [CONTACT_22841]. The frequency  of uncorrected QT values above 
500 ms will be tabulated.
The number (%) of participants with maximum postdose QTc Fvalues and maximum 
increases from baseline in the following categories will be tabulated by  [CONTACT_3148]: 
Safety QTc FAssessment
Degree of Prolongation Mild (ms) Moderate (ms) Severe (m s)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 64If more than 1 ECG is collected at a nominal time after dose administration (for example, 
triplicate ECGs), the mean of the replicate measurements will be used to represent a single 
observation at that time point. I f any  of the 3 individual ECG tracings has a QTc Fvalue 
>500 ms, but the mean of the triplicates is not >500 ms, the data from the participant’s 
individual tracing will be described in a safet y section of the CSR in order to place the 
>500-ms value in appropriate clinical context. However, values from individual tracings 
within triplicate measurements that are >
500mswill not be included in the categorical 
analysis unless the average from the triplicate measurements is also >[ADDRESS_941005] unblinded reviews of the data during the course of the study  for the 
purpose of safet y assessment, facilitating PK/PD modeling, and/or supporting clinica l 
development. 
9.5.Sample Size Determination
A sample size of 12 evaluable participants will provide 90% confidence intervals (CIs) for 
the difference between treatments of ±0.2995 and ±0. 3337 on the natural log scale for AUC inf
and C max, respectively , with 80% coverage probability . Table 7presents the width of 90% CI  
for different estimated effects.
Table 7. Confidence Interval Estimation of PK Endpoints
Param eter Estimated Effect 
(100* Test/Reference)90% CI CI Width
AUC inf 150% 1.1118, 2.0237 0.9119
170% 1.2600, 2.2936 1.0335
180% 1.3342, 2.4285 1.0943
190% 1.4083, 2.5634 1.1551
200% 1.4824, 2.6983 1.2159
210% 1.5565, 2.8332 1.2767
220% 1.6306, 2.9682 1.3375
230% 1.7048, 3.1031 1.3983
250% 1.8530, 3.3729 1.5199
Cmax 150% 1.0744, 2.0942 1.0198
170% 1.2176, 2.3734 1.1558
180% 1.2893, 2.5131 1.2238
190% 1.3609, 2.[ADDRESS_941006] 
(100* Test/Reference)90% CI CI Width
200% 1.4325, 2.7923 1.3598
210% 1.5041, 2.9319 1.4278
220% 1.5758, 3.0715 1.4957
230% 1.6474, 3.2111 1.5637
250% 1.7906, 3.[ADDRESS_941007] deviation of 0.3491 
and 0.3890 for log eAUC tauand log eCmaxrespectively , based on the results from 
Study C4471001.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 6610. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and re gulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsibl e for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an app licable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .

PF-[ADDRESS_941008], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investiga tor 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study , 
including the risks and benefits, to the participant and answer all questions regarding the 
study . The participant sh ould be given sufficient time and opportunity  to ask questions and to 
decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed cons ent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each participant is fully  informed about the natu re and 
objectives of the stud y, the sharing of data related to the study, and possible risks associated 
with participation, including the risks associated with the processing of the participant ’s 
personal data. 
The participant must be informed that their personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that their medical records may  be examined by  [CONTACT_95496] l 
Quality  Assurance auditors or other authorized personnel appointed by  [CONTACT_456], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which 
the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IRB/EC -approved ICD(s) 
during their participation in the s tudy as required per local regulations.
A cop y of the IC D(s) must be provided to the participant.
Participants who are rescreened are required to sign a new IC D
.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 6810.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted elect ronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. An y 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant -specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to their actual identity and medical record ID. In case of data 
transfer, the sponsor will protect the confidentiality of participant s’ per sonal data consistent 
with the c linical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect suc h data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains standard operating procedures on how to respond in the event of 
unauthorized access, use, or disclosure of sponsor information or sy stems.
10.1.4. C ommittees Structure
This study  will not use a n E-DMC.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT /CTI S, and/or 
www.pfizer .com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 69www.clinicaltrials .gov
[COMPANY_007] posts clinical tri al results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submi tted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT /CTI S
[COMPANY_007] posts clinical trial r esults on EudraCT /CTI Sfor [COMPANY_007] -sponsored interventional studies 
in accordance with the format and timelines set forth by  [CONTACT_693761].
www.pfizer .com
[COMPANY_007] posts CSR sy nopses and plain- language study  results summaries on www.pfizer .com 
for [COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results 
areposted to www.clinicaltrials.gov .CSR sy nopses w ill have personally  identifiable 
information anon ymized.
Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes of “bona -fide scientific research” that contribute sto the scientific understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regulat ions. CSRs will have personall y identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electroni c CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].

PF-[ADDRESS_941009] ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent ac cess b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process .
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality , such as risk management and 
mitigation strategies and anal ytical risk-based monitoring), method s, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and/or 
IQMP maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years af ter study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_014] o f such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies th at are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-[ADDRESS_941010] be available at 
the investigative site that identifies those d
ata that will be recorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator , which is maintained by  [CONTACT_456] ’s designee ([COMPANY_007] CRU) .
Descr iption of the use of the computerized sy stem is documented in the Source Document 
Locator, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU ).
The investigator must maintain accurate documentation (source data) that supports the 
information entere d in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; 
that the safet y and rights of participants are being protecte d; and that the study  is being 
conducted in accordance with the currentl y approved protocol and an y other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or ter minate the study  at any  
time for an y reason at the sole discretion of the sponsor ,including (but not limited to) 
regulatory  authorit y decision, change in opi[INVESTIGATOR_2511] I RB/EC, or change in benefit -risk 
assessment .Study  sites will be closed upon study completion. A study  site is considered 
closed when all required documents and study  supplies have been collected and a study -site 
closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 72Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention developmen t.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IRB/ECs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol ,the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 year after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or Pf izer-intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publica tions and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites. I n accordance with stan dard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. I n this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publica tions for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 73If publication is addressed in the clinical study  agreement, the publication policy  setout in 
this section will not apply.
10.1.10. Sponsor’s Medically Qualified Individual
The contact [CONTACT_1133] ’s MQI for the study  is documented in the study  
contact [CONTACT_306925] . 
To facilitate access to their investigator and the sponsor’ s MQI for study -related medical 
questions or problems from nonstudy  healthcare professionals , participants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study  intervention identifiers, (b) par ticipant’s study  identification number and(c) site 
emergency  phone number active 24 hours/day , [ADDRESS_941011] s 
between the participant and their investigator and site staff, and between the investigator and 
sponsor study  team. The ECC is only to be used by  [CONTACT_185624] y, as a means of reaching the investigator or site staff related to the care of a 
participant. 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 7410.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 8. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total proteinLocal dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
cultureaaPTT, PT -INR, eGFR 
(CKD -EPI)
Urine drug screeningc
Urine cotinine test
At screen ingonly:
FSHb
Hepatitis B surface 
antigen
Hepatitis C antibody
Hepatitis B core antibody
HIV
a.Only if UTI is suspected and urine dipstick is positive (1+) for blood, protein, nitrites or leukocyte 
esterase.
b.For confirmation of postmenopausal status only.
c.The minimum requirement for drug screening includes coca ine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (other sare site and study specific).
The table below is a list of reflex safet y laboratory tests, which are required for certain 
circumstances only . This is not an exhaustive list; other special reflex tests may  be added as 
needed.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 75Table 9. Protocol -Required Follow -Up Safety Laboratory Assessments (In Case of 
Abnormality)
Hem atology Chemistry Urinalysis on Site Other
If Hb/RBC abnormal: 
MCV, MCH, MCHC 
Neutrophils (%) 
Eosinophils (%) 
Basophils (%) 
Lymphocytes (%) 
Monocytes (%) 
RBC morphology 
RBC distribution widthRequired :
For suspected DILI :
AST/ALT 
T bili, direct and indirect 
bili 
Total bile acids, GGT 
Total protein, albumin 
CK 
PT, INR 
Acetaminophen/paracetamol 
or 
protein adduct levels 
Hepatitis serology (even if 
screening negative) 
For suspected DICI/DIKI: 
Creatinine (Scr) 
CystatinC (Scys) 
eGFR (Scr only and 
combined Scr+Scys) 
Spot (dipstick ) UACRLocal Laboratory
Microscopy and culture 
for positive local 
dipstick testsaHepatitis B DNA 
Hepatitis C RNA
a.Only if UTI is suspected and urine dipstick is positive for nitrites or leukocyte esterase or both. Any 
positive results are to be reported as an AE.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant change s occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safet y laboratory 
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study .
CCI
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 7610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scie ntific judgment of the investigator. Any 
abnormal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional over dose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 77Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_216472], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or w as 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 78The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, 
pathogenic or non -pathogenic 
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a [COMPANY_007] product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropri ate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_78278], such as significant 
medical events that may jeopardize the participant or may  require medic al or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of A Esand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of event s: (1) SAEs; (2) 
nonserious A Es; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-[ADDRESS_941012] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll A Es/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRFAll instances of EDP are 
reported (whether or not 
there is an associated 
SAE) *
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure 
to the product under 
study  to a 
nonparticipant (not 
involving EDP or EDB)None. Exposure to a study 
non-participant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Repo rt 
Form . 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form ,which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 80It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE C RF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_693746] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: A type of AE that is usually  transient and may  require only  minimal 
treatment or therapeutic intervention. The event does not generally  interfere with 
usual ADL .
Moderate: A t ype of AE that is usually  alleviated with additional specific 
therapeutic intervention. The event interferes with usual ADL , causing 
discomfort , but poses no significant or permanent risk of harm to the research 
participant.
Severe: A t ype of AE that in terrupts usual ADL , or significantly  affects clinical 
status, or may  require intensive therapeutic intervention.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is r ated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship convey s that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 81Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
riskfactors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in their assessment.
For eac h AE or SAE, the investigator must document in the medical notes that 
they have reviewed the AE or SAE and ha veprovided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to includ e in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .
The investigator may  change their opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not kn ow whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, as defined by  [CONTACT_456] . In addition, if the investigator 
determines that an SAE is associated with study procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -Up of A Es and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as po ssible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the in vestigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 82New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within [ADDRESS_941013]
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic DCT .
If the electronic s ystem is unavailable, then the site will use the paper SAE DCT
(see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or 
paper form (as applicable) as soon as t he data become available.
After the stud y is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic DCT has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756]. 
SAE Reporting to [COMPANY_007] Safety via the CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , an alternative method should 
be used, eg , secured (Transport L ayer Security ) or password
-protected email. I f 
none of these methods can be used, notification by [CONTACT_9337] a 
copy  of the CT SAE Report Form sent b y overnight mail or courier service.
Initial notification via teleph one does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 8310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28days after the last dose of study  intervention ,which 
corresponds to the time needed to eliminate reproduc tive safet y risk of the study  
intervention(s): 
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse as their preferred and usual lifesty le 
(abstinent on a long -term and persistent basis) and agree to remain abstinent.
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom , and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception ,as a condom 
may break or leak, when having sexual inter course with a WOCBP who is not 
currentl y pregnant.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 2 ( Section 5.1) and specify  the reproductive 
requirements for including female participants. Refer to Section 10.4.[ADDRESS_941014] of 
contraceptive methods permitted in the study . 
A female participant is eligible to part icipate if she is not a WOCBP (see definition in 
Section 10.4.3) and is not breastfeeding .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If ferti lity is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Preme nopausal female with 1 of the following:
Documented h ysterectomy ;

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 84Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be applied 
to determining stud y entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examinatio n, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highl y effective nonestrogen hormonal contraception methods 
if she wishes to continue herHRT during the study . Otherwise, she must 
discontinue HRT to allow confirmatio n of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study :
Highl y Effective Methods That 
Have Low User Dependency  
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 855.Vasectomized partner.
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90 day s.
Highl y Effective Methods That A re User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal .
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
Sexual Abstinence
8.Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
Other Effective Methods
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10. Male or female condom, with or without spermicide.
11.Cervical cap, diaphragm, or sponge with spermicide.
12.A combi nation of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 86
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 8710.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments 
Potential Cases of Drug Induced -Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “to lerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury , commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI case s, elevations in AST and/or ALT precede T bili elevations 
(>2×ULN) by  [CONTACT_90051] s or weeks. The increase in T bili ty pi[INVESTIGATOR_214318]/AL T is/are still elevated above 3 × ULN (ie, AST/AL T and T bili values will be 
elevated within the same lab oratory sample). In rare instances, by  [CONTACT_29623] T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value ≥ 2 × ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participant s with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values 
≥2times the baseline values AND ≥3 ×ULN; or ≥8 × ULN (whichever is 
smaller).
Preexisting values of T bili above the normal range: T bili leve l increased from 
baseline value b y an amount of ≥1 × ULN orif the value reaches ≥
3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually  based on clinical judgment; any  case where unce rtainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.

PF-[ADDRESS_941015] and AL T and T bilifor suspected Hy’s law 
cases , additional laboratory  tests should include albumin, CK, dir ect and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporane ous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liv
er or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
T bili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 8910.7. Appendix 7: Kidney Safety: Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Funct ion and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to estimate glomerular filtration rate [Scr- based eGFR ]or 
creatinine clearance [eCrCl ]). Baseline and p ostbaseline serum Scy s makes it feasible to 
distinguish AKI from other causes of Scr increase. If Scr increase is confirmed after baseline, 
then reflex measurement of Scy s is indicated to estimate the combined Scr
-Scys eGFR 
calculation (for adults only ).
Regardless of whether kidney  function monitoring tests are required as a routine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  function, then these test result s should be managed 
and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD- EPI [INVESTIGATOR_185560]
2021 CKD -
EPI, Scr OnlyScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 N/A eGFR = 143 × (Scr/0.7)-0.241× (0.9938)Age
Female if > 0.7 N/A eGFR = 143 × (Scr/0.7)-1.200× (0.9938)Age
Male if ≤ 0.9 N/A eGFR = 142 × (Scr/0.9)-0.302× (0.9938)Age
Male if > 0.9 N/A eGFR = 142 × (Scr/0.9)-1.200× (0.9938)Age
2021 CKD -
EPI, Scr-Scys 
CombinedScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 if ≤ 0.8 eGFR = 130 × (Scr/0.7)-0.219× (Scys/0.8)-0.323× (0.9961)Age
Female if ≤ 0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.219× (Scys/0.8)-0.778× (0.9961)Age
Female if > 0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.544× (Scys/0.8)-0.323× (0.9961)Age
Female if > 0.7 if > 0.8 eGFR = 130 × (Scr/0.7)-0.544× (Scys/0.8)-0.778× (0.9961)Age
Male if ≤ 0.9 if ≤ 0.8 eGFR = 135 × (Scr/0.9)-0.144× (Scys/0.8)-0.323× (0.9961)Age
Male if ≤ 0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.144× (Scys/0.8)-0.778× (0.9961)Age
Male if > 0.9 if ≤ 0.8 eGFR = 135 × (Scr/0.9)-0.544×(Scys/0.8)-0.323× (0.9961)Age
Male if > 0.9 if > 0.8 eGFR = 135 × (Scr/0.9)-0.544×(Scys/0.8)-0.778× (0.9961)Age
Inker LA et al. N Engl J Med. 2021;385:1737-49.
10.7.3. Adverse Event Grading for Kidney Safety Lab oratory Abnormalities
AEgrading for decline in kidney  function (ie, eGFR or eCrCl) will be according to CTCAE
criteria.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 9010.8. Appendix 8: ECG Findings of Potential Clin ical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus brad ycardia (rate <40 bpm) lasting minutes .
New PR interval prolongation >280 ms.
New prolongation of QTcF to >480 ms (absolute) or by  ≥60 ms from baseline .
New -
onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset t ype I second -degree -(Wenckebach) AV block of >30 seconds ’
duration
.
Frequent PVCs, triplets ,or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms .
New ST- T changes suggestive of my ocardial ischemia .
New -onset LBBB (QRS complex >120 ms) .
New -
onset right bundle b ranch block (QRS complex >120 ms) .
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia
with [ADDRESS_941016] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) ( “sustained ”= short 
duration with relevant s ymptom s or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( HR
<40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 91monomorphic/poly morphic ventricular tachycardia (HR >100 bpm [such as
torsades de pointes]).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the 
discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all-inclusive of what to be reported as AEs/SAEs.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 9210.9. Appendix 9: Prohibited Concomitant Medications That May Result inDDI
The prohibited concomitant medications listed below should not be taken with PF-
[ADDRESS_941017] of drugs prohibited for potential DDI concerns with the IMP may  be revised during 
the course of the study  with written notifica tion from sponsor, to include or exclude specific 
drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, 
availability  of new information in literature on the DDI potential of other drugs).
This is not an all -inclusive list. Si te staff should consult with the sponsor or designee with 
any questions regarding potential DDI.
Investigators should consult the product label for any  other medication used during the study  
for information regarding medication that is prohibited for conco mitant use. 
Table 10. Prohibited Concomitant Medications that May Result in DDI
Drug Category Drugs Guidance Required Washout 
Period Prior to the First 
Dose of PF -[ADDRESS_941018] a 
narrow
therapeutic index 
(NTI) alfentanil
amiodarone
argatroban
astemizolea
carbamazepi[INVESTIGATOR_693747] N/A
CCI
PF-[ADDRESS_941019] 
Dose of PF -07284890
ergotamine
fentanyl (excluding 
transdermal patch)
pi[INVESTIGATOR_693748]
a.Not approved in the US as of October 2020, but may be available in other countries including Korea, 
China and Mexico.

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 9410.10. Appendix 1 0: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
%CV percent coefficient of variation
Abs absolute
ADL activity /activities of dail y living
AE adverse event
AESI adverse event of special interest
AKI acute kidney  injury
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
ATC aanaplastic th yroid cancer
AUC area under the plasma concentration -time curve
AUC 24hr area under the plasma concentration -time curve from time zero to 
24hours
AUC inf area under the plasma concentration- time curve from time zero 
extrapolated to infinity
AUC last area under the plasma concentration -time profile from time zero to 
the time of the last quantifiable concentration (Clast).
AUC tau area under the plasma concentration -time curve from time zero to 
tau(ie, over the dosing interval)
AV atrioventricular
AxMP auxiliary  medicinal product
BBS Biospecimen Banking S ystem
BCRP breast cancer resistance protein
BID twice dail y
BLRM Bayesian Logistic Regression Model
BMI body  mass index
BP blood pressure
bpm beats per minute
BRAF B-type Raf proto -oncogene
BRAFi B-type Raf proto -oncogene inhibitor
BUN blood urea nitrogen
C1D1 Cycle 1 Day  1
C1D15 Cycle 1 Day  15
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_693749]-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 95Abbreviation Term
CL/F apparent clearance
Clast the last quantifiable concentration
Cmax maximum observed concentration
CNS central nervous system
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_941020] European Union Drug Regulating Authorities Clincal Trials 
(European Clinical Trials Database)
FIH first in human

PF-[ADDRESS_941021] non -severely  toxic dose
HR heart rate
HRT hormone replacement therap y
HV healthy  volunteer
IB Investigator’s Brochure
IC50 half-maximal inhibitory  concentration
IC90 90% of the maximum inhibition concentration
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IPAL Investigational Product Accountability  Log
IPM investigational product manual
IQMP Integrated Quality  Management Plan
IRB Institutional Review Board
IV intravenous(l y)
K2-EDTA dipotassium ethy lenediaminetetraacetic acid
Kel terminal phase rate constant
LBBB left bundle branch block
LFT liver function test
MAPK mitogen -activated protein kinase
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MEK mitogen/extracellular signal regulated kinase
NHP nonhuman primate 
MOE margin of exposure

PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 97Abbreviation Term
MQI medically  qualified individual
MTD maximum tolerated dose
N/A not applicable
ND no data
NIMP noninvestigational medicinal product
NOAEL no-observed -adverse -effect level
NSCL C non-small cell lung cancer
NTI narrow therapeutic index
OCT optical coherence tomography
PCR polymerase chain reaction
PCRU [COMPANY_007] Clinical Research Unit
PD pharmacod ynamic(s)
PE physical examination
PFS progression -free survival
PI [INVESTIGATOR_19959](s)
PPI [INVESTIGATOR_693750]'s Serious Adverse Event Submission Assistant
PT prothrombin time
PTC papi[INVESTIGATOR_693751]/complex
QD once dail y
QRS time from ECG Q wave to the end of the S wave corresponding to 
ventricle depolarization
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
qual qualitative
RAUC accumulation ratio based on AUC
RBC red blood cell
RCmax accumulation ratio based on Cmax
RDE recommended dose for expansion
RNA ribonucleic acid
RPED retinal pi[INVESTIGATOR_693752]-PCR reverse transcriptase -polymerase chain reaction
RVO retinal vein occlusion
SAE serious adverse event
SAP Statistical Analy sis Plan
SARS -CoV -[ADDRESS_941022] operating procedure
SRS stereotactic radiosurgery
SRSD Single Reference Safety Document
STD 10 severel y toxic dose in 10% of the animals
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t½ terminal elimination half -life
T bili total bilirubin
TEAE treatment -emergent adverse event
THC tetrah ydrocannabinol
TK toxicokinetics
Tmax time to reach C max
UACR urine albumin/creatinine ratio
ULN upper limit of normal
US [LOCATION_002]
UTI urinary  tract infection
UVB ultraviolet B
Vz/F apparent volume of distribution for extravascular dosing
WBC white blood cell
WOCBP woman/women of childbearing potential
WBRT whole -brain radiotherapy
CCI
PF-07284890
Protocol C4471002
Final Protocol, 06 April2022
PFIZER CONFIDENTIAL
Page 9911.REFERENCES
1. Stelzer KJ. Epi[INVESTIGATOR_693753]. Surg Neurol Int 
2013;4(Suppl 4):S192-202.
2. Barnholtz -Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain 
metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer 
Surveillance System. J Clin Oncol 2004;22(14):2865 -72.
3. Cohen JV, Tawbi H, Margolin KA, et al. Melanoma central nervous s ystem metastases: 
current approaches, challenges, and opportunities. Pi[INVESTIGATOR_79306] 
2016;29(6):627 -42.
4. Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to 
the brain from non- small cell lung carcinoma: primary  tumor size, cell ty pe, and l ymph 
node metastases. Radiology  2007;242(3):882 -8.
5. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with 
BRAFV600-mutant melanoma brain metastases (COMBI- MB): a multicentre, 
multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73.
6. Ascierto PA, McArthur GA, Dr énoB, et al. Cobimetinib combined with vemurafenib in 
advanced BRAF(V600) -mutant melanoma (coBRIM): updated efficacy results from a 
randomised, double -blind, phase 3 trial. Lancet Oncol 2016;17(9):1248 -60.
7. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-
mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or 
encorafenib (COLUMBUS): a multicentre, open -label, randomised, phase 3 trial. 
Lancet Oncol 2018;19(10):1315 -27.
8. McArthur GA, Maio M, Arance A, et al. Ve murafenib in metastatic melanoma patients 
with brain metastases: an open -label, single -arm, phase 2, multicentre study . Ann Oncol 
2017;28(3):634 -41.
9. Holbrook K, Lutzky  J, Davies MA, et al. Intracranial antitumor activity  with 
encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. 
Cancer 2020;126(3):[ADDRESS_941023] for 
cancer (immuno -)therapy. Virchows Arch 2019;474(4):497 -509.
11. Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or 
without whole brain radiotherap y in treating patients with non -small cell lung cancer 
with brain metastases unsuitable for resection or stereotactic radiotherap y (QUARTZ): 
results from a phase 3, non- inferiorit y, randomised trial. Lancet 2016;388([ZIP_CODE]):[ADDRESS_941024], and gastric pH -dependent drug interactions . AAPS J. 2021; 24(1): 16. 
15. FDA Draft Guidance, 
Guidance for Industry : Assessing the Effects of Food on Drugs in 
INDs and NDAs —Clinical Pharmacology  Considerations. Available from : 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/assessing -
effects -food-drugs- inds- and-ndas-clinical -pharmacology -considerations . Published: Mar 
2019. Accessed: Mar 2022 .
16. “Metabolism and Transport, Drug Interaction Database”, Depa
rtment of Pharmaceutics, 
University  of Washington. www. druginteractionsolutions.org. Accessed: May 2009.
17. FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and 
Inducers. Available from 
http://courses.washington.edu/medch527/PDFs/L iterature/527_fdatable.pdf. Accessed :
Mar 2022 :
18. Daly  AK, Rettie AE, Fowler DM, et al. Pharmacogenomics of CYP2C9: functional and 
clinical considerations. J Pers Med 2017;8(1):1- 31.
CCI